

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 407 774 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

14.04.2004 Bulletin 2004/16

(51) Int Cl.7: **A61K 31/517**, C07D 239/95,

C07D 401/12, C07D 403/04,

A61P 3/06

(21) Application number: 02020255.2

(22) Date of filing: 10.09.2002

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR

Designated Extension States:

AL LT LV MK RO SI

(71) Applicant: LION bioscience AG

69123 Heidelberg (DE)

• Koegl, Manfred

69214 Eppenheim (DE)

• Kremoser, Claus

69121 Heidelberg (DE)

• Kober, Ingo

69251 Gaiberg (DE)

• Bauer, Ulrike

69207 Sandhausen (DE)

• Giegrich, Kristina

68623 Lampertheim (DE)

(72) Inventors:

• Deuschle, Ulrich

69245 Bammental (DE)

• Loebbert, Ralph

69115 Heidelberg (DE)

• Blume, Beatrix

69221 Dossenheim (DE)

(74) Representative: Goddar, Heinz J., Dr. et al

FORRESTER & BOEHMERT

Pettenkoferstrasse 20-22

80336 München (DE)

(54) 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds

(57) The present invention relates to 2-amino-4-oxo-quinazolines which bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medi-

caments using said compounds. In particular the compounds are useful in the treatment of hypercholesterolemia, obesity or other diseases associated with elevated lipoprotein (LDL) levels.

EP 1 407 774 A1

Description

5 [0001] The present invention relates to compounds according to the general formula (1), which bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.

BACKGROUND OF THE INVENTION

10 [0002] Multicellular organisms are dependent on advanced mechanisms of information transfer between cells and body compartments. The information that is transmitted can be highly complex and can result in the alteration of genetic programs involved in cellular differentiation, proliferation, or reproduction. The signals, or hormones, are often simple molecules, such as peptides, fatty acid, or cholesterol derivatives.

15 [0003] Many of these signals produce their effects by ultimately changing the transcription of specific genes. One well-studied group of proteins that mediate a cell's response to a variety of signals is the family of transcription factors known as nuclear receptors, hereinafter referred to often as "NR". Members of this group include receptors for steroid hormones, vitamin D, ecdysone, cis and trans retinoic acid, thyroid hormone, bile acids, cholesterol-derivatives, fatty acids (and other peroxisomal proliferators), as well as so-called orphan receptors, proteins that are structurally similar to other members of this group, but for which no ligands are known (Escriva, H. et al., Ligand binding was acquired during evolution of nuclear receptors, PNAS, 94, 6803 - 6808, 1997). Orphan receptors may be indicative of unknown signaling pathways in the cell or may be nuclear receptors that function without ligand activation. The activation of transcription by some of these orphan receptors may occur in the absence of an exogenous ligand and/or through signal transduction pathways originating from the cell surface (Mangelsdorf, D. J. et al., The nuclear receptor superfamily: the second decade, Cell 83, 835-839, 1995).

20 [0004] In general, three functional domains have been defined in NRs. An amino terminal domain is believed to have some regulatory function. A DNA-binding domain hereinafter referred to as "DBD" usually comprises two zinc finger elements and recognizes a specific Hormone Responsive Element hereinafter referred to as "HRE" within the promoters of responsive genes. Specific amino acid residues in the "DBD" have been shown to confer DNA sequence binding specificity (Schena, M. & Yamamoto, K.R., Mammalian Glucocorticoid Receptor Derivatives Enhance Transcription in Yeast, Science, 241:965-967, 1988). A Ligand-binding-domain hereinafter referred to as "LBD" is at the carboxy-terminal region of known NRs. In the absence of hormone, the LBD of some but not all NRs appears to interfere with the interaction of the DBD with its HRE. Hormone binding seems to result in a conformational change in the NR and thus opens this interference (Brzozowski et al., Molecular basis of agonism and antagonism in the oestrogen receptor, Nature, 389, 753 - 758, 1997; Wagner et al., A structural role for hormone in the thyroid hormone receptor, Nature, 378, 690 - 697, 1995). A NR without the HBD constitutively activates transcription but at a low level.

25 [0005] Coactivators or transcriptional activators are proposed to bridge between sequence specific transcription factors and the basal transcription machinery and in addition to influence the chromatin structure of a target cell. Several proteins like SRC-1, ACTR, and Grip1 interact with NRs in a ligand enhanced manner (Heery et al., A signature motif in transcriptional coactivators mediates binding to nuclear receptors, Nature, 387, 733 - 736; Heinzel et al., A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression, Nature 387, 43 - 47, 1997). Furthermore, the physical interaction with repressing receptor-interacting proteins or corepressors has been demonstrated (Xu et al., Coactivator and Corepressor complexes in nuclear receptor function, Curr Opin Genet Dev, 9 (2), 140 - 147, 1999).

30 [0006] Nuclear receptor modulators like steroid hormones affect the growth and function of specific cells by binding to intracellular receptors and forming nuclear receptor-ligand complexes. Nuclear receptor-hormone complexes then interact with a hormone response element (HRE) in the control region of specific genes and alter specific gene expression.

35 [0007] The term LXR (Liver X Receptor) includes all subtypes of this receptor. Specifically LXR includes LXRA (also known as LXRalpha, RLD-1 and NR1H3) and LXRb (also known as LXRbeta, NER, NER1, UR, OR-1, R1P15 and NH1H2) and ligands of LXR should be understood to include ligands of LXRA or LXRb. LXR is a prototypical type 2 nuclear receptor which activates genes upon binding to promoter region of target genes in a prototypical heterodimeric fashion with Retinoid X Receptor (hereinafter RXR, Forman et al., Cell, 81, 687-93, 1995). The relevant physiological ligands of LXR seem to be oxidized derivatives of cholesterol, including 22-hydroxycholesterol and 24,25(S)-epoxycholesterol (Lehmann, et al., Biol. Chem. 272(6), 3137-40, 1997). The oxysterol ligands bound to LXR were found to regulate the expression of several genes that participate in cholesterol metabolism (Janowski, et al., Nature, 383, 728-31, 1996).

40 [0008] LXR is proposed to be a hepatic oxysterol sensor. Upon activation (e.g. binding of oxysterols) it influences the conversion of dietary cholesterol into bile acids by upregulating the transcription of key genes which are involved

in bile acid synthesis such as CYP7A1. Hence, activation of LXR in the liver could result in an increased synthesis of bile acids from cholesterol which could lead to decreased levels of hepatic cholesterol. This proposed LXR function in hepatic cholesterol metabolism was experimentally confirmed using knockout mice. Mice lacking the receptor LXRA lost their ability to respond normally to an increase in dietary cholesterol and did not induce transcription of the gene encoding CYP7A1. This resulted in accumulation of large quantities of cholesterol in the livers and impaired hepatic function. (Peet, et al., Cell, 93, 693-704, 1998).

[0009] Besides its important function in liver, LXR plays an important role in the regulation of cholesterol homeostasis in macrophages and intestinal mucosa cells where it upregulates cholesterol transporters from the ABC (=ATP binding cassette) family of membrane proteins (Repa, et al., J Biol Chem. 2002 May 24;277(21):18793-800). These transporters are believed to be crucially involved in the uptake of cholesterol from the diet since mutations in their genes leads to diseases such as sitosterolemia (Berge, et al., Science (2000);290(5497):1771-5.).

[0010] Other members of the ABC transporter family seem to be responsible for the efflux of cholesterol from loaded macrophages, a process which is thought to prevent the generation of atherosclerotic lesions. Stimulation of LXR by synthetic ligands might result in an increased cholesterol efflux from macrophages and a decreased deposition of atherosclerotic plaques (Venkateswaran, et al., PNAS (2000) 24;97(22):12097-102; Sparrow, et al., J Biol Chem (2002) 277(12):10021-7; Joseph, et al., PNAS (2002);99(11):7604-9).

[0011] However, in animal studies it was observed that activation of LXR in the liver by full agonists does not only increase bile acid synthesis but also stimulates the de novo synthesis of fatty acids and triglycerids through the up-regulation of key enzymes such as Fatty Acid Synthase (FAS) or Stearyl-CoA Desaturase (SCD-1). (Schultz, et al., Genes Dev (2000) 14(22):2831-8.

[0012] Therefore, an ideal synthetic LXR binding compound should have properties that retain the agonistic activity on hepatic bile acid formation and ABC-transporter -mediated decrease in cholesterol uptake from the diet and increased cholesterol efflux from macrophages. In parallel such a compound should lack the hyperlipidemic potential which is exerted through increased fatty acid and triglyceride synthesis.

[0013] To date few compounds have been described which bind the LXR receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor (Collins, et al., J Med Chem. (2002) 45 (10):1963-6; Schultz, et al., Genes Dev (2000) 14(22):2831-8; Sparrow, et al., J Biol Chem (2002) 277(12):10021-7).

[0014] It was thus an object of the present invention to provide for compounds which by means of binding the LXR receptor act as agonist, antagonist or mixed agonist / antagonist of said receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor.

[0015] It was further an object of the invention to provide for compounds that may be used for the manufacture of a medicament for the treatment of cholesterol associated conditions or diseases. In a preferred embodiment of the invention it was an object of the invention to provide for compounds that lower serum cholesterol and/or increase High Density lipoproteins (HDL) and/or decrease Low Density Lipoproteins (LDL). It was also an object of the invention to provide for compounds that may be used for the treatment of lipid disorders including hypercholesterolemia, atherosclerosis, Alzheimer's disease, skin disorders, obesity and diabetes.

SUMMARY OF THE INVENTION

[0016] The present invention provides, *inter alia*, novel LXR nuclear receptor protein binding compounds according to the general formula (1) shown below. Said compounds are also binders of mammalian homologues of said receptor. Further the object of the invention was solved by providing for amongst the LXR nuclear receptor protein binding compounds according to the general formula (1) such compounds which act as agonists, antagonists or mixed agonists / antagonists of the human LXR receptor or a mammalian homologue thereof.


[0017] The invention provides for LXR agonists that may be used for the manufacture of a medicament for the treatment of cholesterol associated conditions or diseases. In a preferred embodiment of the invention it was an object of the invention to provide for compounds that lower serum cholesterol and/or increase High Density lipoproteins (HDL) and/or decrease Low Density Lipoproteins (LDL). It was also an object of the invention to provide for compounds that may be used for the treatment of lipid disorders including hypercholesterolemia, atherosclerosis, Alzheimer's disease, skin disorders, obesity and diabetes.

[0018] The foregoing merely summarizes certain aspects of the present invention and is not intended, nor should it be construed, to limit the invention in any manner. All patents and other publications recited herein are hereby incorporated by reference in their entirety.

55 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] The invention provides for a compound according to the following formula (1), or pharmaceutical acceptable salts or solvates thereof, hereinafter also referred to as the "compounds according to the invention" including particular

and preferred embodiments thereof, wherein



R₁, R₂, R₃ and/or R₄, is independently from each other selected from H, halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-(C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, such that, for example, a biphenyl results. R₅ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, R₆ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, R₇ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, R₆ and R₇ may be taken together with nitrogen to form a heterocycle or substituted heterocycle or a heteroaryl or substituted heteroaryl ring.

[0020] The compounds of the invention can also exist as solvates and hydrates. Thus, these compounds may crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention.

[0021] The symbol "H" denotes a hydrogen atom.

[0022] The term "C₁ to C₇ acyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, benzoyl and the like. Preferred acyl groups are acetyl and benzoyl.

[0023] The term "C₁ to C₇ substituted acyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₇ alkoxy, C₁ to C₇ acyl, C₁ to C₇ acyloxy, nitro, C₁ to C₆ alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, cyano, methylsulfonyl amino, thiol, C₁ to C₄ alkylthio or C₁ to C₄ alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

[0024] The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-(C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, such that, for example, a biphenyl results.

[0025] Examples of the term "substituted phenyl" includes a mono- or di(halo)phenyl group such as 2, 3 or 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2, 3 or 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 or 4-fluorophenyl and the like; a mono or di(hydroxy)phenyl group such as 2, 3 or 4-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2, 3 or 4-nitrophenyl; a cyanophenyl group, for example, 2, 3 or 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as 2, 3 or 4-methylphenyl, 2,4-dimethylphenyl, 2, 3 or 4-(iso-propyl)phenyl, 2, 3 or 4-ethylphenyl, 2, 3 or 4-(n-propyl)phenyl and the like; a mono or di(alkoxy)phenyl group, for example, 2,6-dimethoxyphenyl, 2, 3 or 4-methoxyphenyl, 2, 3 or 4-ethoxyphenyl, 2, 3 or 4-(isopropoxy)phenyl, 2, 3 or 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl and the like; 2, 3 or 4-trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such as 2, 3 or 4-carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono- or di(hydroxymethyl)phenyl or (protected hydroxymethyl)phenyl such as 2, 3, or 4-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or (protected aminomethyl)phenyl such as 2, 3 or 4-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-(methylsulfonyl)amino)phenyl such as 2, 3 or 4-(N-(methylsulfonyl)amino)phenyl. Also, the term

"substituted phenyl" represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy 4-chlorophenyl and the like.

[0026] The term "heteroaryl" means a heterocyclic aromatic derivative which is a five-membered or six-membered 5 ring system having from 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms.

[0027] Examples of heteroaryls include pyridinyl, pyrimidinyl, and pyrazinyl, pyridazinyl, pyrrolo, furano, thiopheno, oxazolo, isoxazolo, phthalimido, thiazolo and the like.

[0028] The term "substituted heteroaryl" means the above-described heteroaryl is substituted with, for example, one 10 or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino groups.

[0029] The term "substituted naphthyl" specifies a naphthyl group substituted with one or more, and preferably one 20 or two, moieties either on the same ring or on different rings chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₇ alkoxy, C₁ to C₇ acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino.

[0030] Examples of the term "substituted naphthyl" includes a mono or di(halo)naphthyl group such as 1, 2, 3, 4, 5, 25 6, 7 or 8-chloronaphthyl, 2, 6-dichloronaphthyl, 2, 5-dichloronaphthyl, 3, 4-dichloronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-bromonaphthyl, 3, 4-dibromonaphthyl, 3-chloro-4-fluoronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-fluoronaphthyl and the like; a mono or di(hydroxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-hydroxynaphthyl, 2, 4-dihydroxynaphthyl, the protected-hydroxy derivatives thereof and the like; a nitronaphthyl group such as 3- or 4-nitronaphthyl; a cyanonaphthyl group, for example, 1, 2, 3, 4, 5, 6, 7 or 8-cyanonaphthyl; a mono- or di(alkyl)naphthyl group such as 2, 3, 4, 5, 6, 7 or 30 8-methylnaphthyl, 1, 2, 4-dimethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropyl)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(n-propyl)naphthyl and the like; a mono or di(alkoxy)naphthyl group, for example, 2, 6-dimethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-methoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 35 8-(isopropoxy)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(t-butoxy)naphthyl, 3-ethoxy-4-methoxynaphthyl and the like; 1, 2, 3, 4, 5, 6, 7 or 8-trifluoromethylnaphthyl; a mono- or di-carboxynaphthyl or (protected carboxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-carboxynaphthyl or 2, 4-di-(protected carboxy)naphthyl; a mono- or di(hydroxymethyl)naphthyl or (protected hydroxymethyl)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(protected hydroxymethyl)naphthyl or 3, 4-di(hydroxymethyl)naphthyl; a mono- or di(amino)naphthyl or (protected amino)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(amino)naphthyl or 2, 4-(protected amino)-naphthyl, a mono- or di(aminomethyl)naphthyl or (protected aminomethyl)naphthyl such as 2, 3, or 4-(aminomethyl)naphthyl or 2, 4-(protected aminomethyl)-naphthyl; or a mono- or di-(N-methylsulfonylamino) naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(N-methylsulfonylamino)naphthyl. Also, the term "substituted naphthyl" represents disubstituted naphthyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxynaphth-1-yl, 3-chloro-4-hydroxynaphth-2-yl, 2-methoxy-4-bromonaphth-1-yl, 4-ethyl-2-hydroxynaphth-1-yl, 3-hydroxy-4-nitronaphth-2-yl, 2-hydroxy-4-chloronaphth-1-yl, 2-methoxy-7-bromonaphth-1-yl, 4-ethyl-5-hydroxynaphth-2-yl, 3-hydroxy-8-nitronaphth-2-yl, 2-hydroxy-5-chloronaphth-1-yl and the like.

[0031] The term "C₁ to C₈ alkyl" denotes such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, amyl, tert-amyl, hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 2-methyl-hexyl, 2-methyl-2hexyl, 2-methyl-3-hexyl, n-octyl and the like.

[0032] Examples of the above substituted alkyl groups include the 2-oxo-prop-1-yl, 3-oxo-but-1-yl, cyanomethyl, 50 nitromethyl, chloromethyl, hydroxymethyl, tetrahydropyranoxymethyl, trityloxymethyl, propionyloxymethyl, amino, methylamino, aminomethyl, dimethylamino, carboxymethyl, allyloxycarbonylmethyl, allyloxycarbonylaminomethyl, methoxymethyl, ethoxymethyl, t-butoxymethyl, acetoxymethyl, chloromethyl, bromomethyl, iodomethyl, trifluoromethyl, 6-hydroxyhexyl, 2,4-dichloro(n-butyl), 2-aminopropyl, 1-chloroethyl, 2-chloroethyl, 1- bromoethyl, 2-chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 1- iodoethyl, 2-iodoethyl, 1-chloropropyl, 2-chloropropyl, 3- chloropropyl, 1-bromopropyl, 2-bromopropyl, 3-bromopropyl, 1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1- iodopropyl, 2-iodopropyl, 3-iodopropyl, 2-aminoethyl, 1- aminoethyl, N-benzoyl-2-aminoethyl, N-acetyl-2-aminoethyl, N-benzoyl-1-aminoethyl, N-acetyl-1-aminoethyl and the like.

[0033] The term "C₁ to C₈ substituted alkyl" denotes that the above C₁ to C₈ alkyl groups are substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, C₃ to C₇ cycloalkyl, naphthyl,

amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₇ alkoxy, C₁ to C₇ acyl, C₁ to C₇ acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N,N-di(C₁ to C₆ alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C₁ to C₄ alkylthio or C₁ to C₄ alkylsulfonyl groups. The substituted alkyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

[0034] The term "C₇ to C₁₂ phenylalkyl" denotes a C₁ to C₆ alkyl group substituted at any position by a phenyl, substituted phenyl, heteroaryl or substituted heteroaryl. Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl(n-propyl), 4-phenylhexyl, 3-phenyl(n-amyl), 3-phenyl(sec-butyl) and the like. Preferred C₇ to C₁₂ phenylalkyl groups are the benzyl and the phenylethyl groups.

[0035] The term "C₇ to C₁₂ substituted phenylalkyl" denotes a C₇ to C₁₂ phenylalkyl group substituted on the C₁ to C₆ alkyl portion with one or more, and preferably one or two, groups chosen from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-(C₁ to C₆ dialkyl)carboxamide, cyano, N-(C₁ to C₆ alkylsulfonyl)amino, thiol, C₁ to C₄ alkylthio, C₁ to C₄ alkylsulfonyl groups; and/or the phenyl group may be substituted with one or more, and preferably one or two, substituents chosen from halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl) carboxamide, protected N-(C₁ to C₆ alkyl) carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, cyclic C₂ to C₇ alkylene or a phenyl group, substituted or unsubstituted, for a resulting biphenyl group. The substituted alkyl or phenyl groups may be substituted with one or more, and preferably one or two, substituents which can be the same or different.

[0036] Examples of the term "C₇ to C₁₂ substituted phenylalkyl" include groups such as 2-phenyl-1-chloroethyl, 2-(4-methoxyphenyl)ethyl, 4-(2,6-dihydroxy phenyl)n-hexyl, 2-(5-cyano-3-methoxyphenyl)n-pentyl, 3-(2,6-dimethylphenyl)n-propyl, 4-chloro-3-aminobenzyl, 6-(4-methoxyphenyl)-3-carboxy(n-hexyl), 5-(4-aminomethylphenyl)-3-(aminomethyl)n-pentyl, 5-phenyl-3-oxo-n-pent-1-yl and the like.

[0037] As outlined above R₆ and R₇ may be taken together with nitrogen to form a heterocycle or substituted heterocycle of the following kind aziridine, azetidine, pyrrolidine, 3-methylpyrrolidine, 3-aminopyrrolidine, 3-hydroxypyrrrolidine, pyrazolidine, imidazolidine, piperidine, 2-methylpiperidine, piperazine, morpholine, azepine, tetrahydroisoquinoline

[0038] The term "heterocycle" or "heterocyclic ring" denotes optionally substituted five-membered to eight-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered to eight-membered rings may be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred. Preferred heterocyclic rings include morpholino, piperidinyl, piperazinyl, 2-amino-imidazoyl, tetrahydrofuran-yl, pyrrolo, tetrahydrothiophen-yl, hexylmethyl-eneimino and heptylmethyleneimino.

[0039] The term "substituted heterocycle" or "substituted heterocyclic ring" means the above-described heterocyclic ring is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₁₂ alkyl, C₁ to C₁₂ alkoxy, C₁ to C₁₂ substituted alkoxy, C₁ to C₁₂ acyl, C₁ to C₁₂ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino carboxamide, protected carboxamide, N-(C₁ to C₁₂ alkyl)carboxamide, protected N-(C₁ to C₁₂ alkyl)carboxamide, N, N-di(C₁ to C₁₂ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₁₂ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, heterocycle or substituted heterocycle groups.

[0040] The term "C₁ to C₈ alkoxy" as used herein denotes groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups. A preferred alkoxy is methoxy. The term "C₁ to C₈ substituted alkoxy" means the alkyl portion of the alkoxy can be substituted in the same manner as in relation to C₁ to C₈ substituted alkyl.

[0041] The term "C₁ to C₈ aminoacyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, octanoyl, benzoyl and the like.

[0042] The term "C₁ to C₈ substituted aminoacyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₁₂ alkoxy, C₁ to C₁₂ acyl, C₁ to C₁₂ acyloxy, nitro, C₁

to C₁₂ alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₁₂ alkyl) carboxamide, protected N-(C₁ to C₁₂ alkyl)carboxamide, N,N-di(C₁ to C₁₂ alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C₁ to C₁₀ alkylthio or C₁ to C₁₀ alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

5 [0043] Examples of C₁ to C₈ substituted acyl groups include 4-phenylbutyroyl, 3-phenylbutyroyl, 3-phenylpropanoyl, 2- cyclohexanylacetyl, cyclohexanecarbonyl, 2-furanoyl and 3-dimethylaminobenzoyl.

10 [0044] This invention provides a pharmaceutical composition comprising an effective amount of a compound according to the invention. Such compounds can be administered by various routes, for example oral, subcutaneous, intramuscular, intravenous or intracerebral. The preferred route of administration would be oral at daily doses of the compound for adult human treatment of about 0.01 -5000 mg, preferably 1-1500 mg per day. The appropriate dose may be administered in a single dose or as divided doses presented at appropriate intervals for example as two, three four or more subdoses per day.

15 [0045] For preparing pharmaceutical compositions containing compounds of the invention, inert, pharmaceutically acceptable carriers are used. The pharmaceutical carrier can be either solid or liquid. Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.

[0046] A solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

20 [0047] In powders, the carrier is generally a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

[0048] For preparing pharmaceutical composition in the form of suppositories, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient-sized molds and allowed to cool and solidify.

25 [0049] Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient. Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter and the like.

[0050] The pharmaceutical compositions can include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier, which is thus in association with it. In a similar manner, cachets are also included. Tablets, powders, 30 cachets, and capsules can be used as solid dosage forms suitable for oral administration.

[0051] Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, or suspensions, and emulsions suitable for oral administration. Sterile water solutions of the active component or sterile solutions of the active component in solvents comprising water, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration.


35 [0052] Sterile solutions can be prepared by dissolving the active component in the desired solvent system, and then passing the resulting solution through a membrane filter to sterilize it or, alternatively, by dissolving the sterile compound in a previously sterilized solvent under sterile conditions.

[0053] In one embodiment of the present invention a compound is claimed according to formula (1) above, or pharmaceutical acceptable salts or solvates thereof, wherein R₁, R₂, R₃, R₄, is H, halogen, hydroxy, protected hydroxy, 40 cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, 45 hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted) amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N- (phenylsulfonyl)amino or phenyl, R₅ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, R₆ and R₇ may be taken together with nitrogen to form the heterocycle according to formula (2),

50

formula (2)

55




[0054] In a preferred embodiment of the invention a compound is provided, or pharmaceutical acceptable salts or solvates thereof, wherein R₁, R₂, R₃, R₄, is H, halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-(C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, R₅ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, R₆ and R₇ may be taken together with nitrogen to form the heterocycle according to formula (2) shown above.

[0055] A particularly preferred compound which may act as agonist of LXR is shown in formula (6) below. The inventors have been able to demonstrate that the compound according to formula (3) has a low effective concentration at LXR with an EC₅₀ of 0.5 μ M wherein the EC₅₀ reflects the half-maximal effective concentration, and which is higher than the EC₅₀ of 0.015 μ M for the published LXR agonist TO901317 (J. Schultz et al., Genes Dev. 14, 2831-2838, 2000)

15

formula (3) (MOLNAME 3252)




25

[0056] The inventors have also found the compounds according to formula (4, 5 and 6) (shown below) to be active as agonist of the LXR human nuclear receptor (see figures for details).

30

formula (4) (MOLNAME 7459)



40

formula (5) (MOLNAME 6584)

45

50

55

5




10

formula (6)) (MOLNAME 7364)

15

20



25

[0057] In particular the invention relates to a compound as described above wherein said compounds is capable of binding the LXR receptor protein or a portion thereof according to SEQ ID NO. 1 (Fig. 3 A to F) or a mammalian homologue thereof. The claimed compound can bind to the LXR receptor protein or a portion thereof in a mixture comprising 10-200 ng of LXR receptor protein, a fusion protein containing LXR or a portion thereof, preferably the ligand binding domain, fused to a Tag, 5-100 mM Tris /HCl at pH 6,8-8,3 ; 60-1000 mM KCl; 0-20 mM MgCl₂; 100-1000ng/μl BSA in a total volume of preferably about 25 μl.).

[0058] A mammalian receptor protein homologue of the protein according to SEQ ID NO. 1 as used herein is a protein that performs substantially the same task as LXR does in humans and shares at least 40% sequence identity at the amino acid level, preferably over 50 % sequence identity at the amino acid level more preferably over 65 % sequence identity at the amino acid level, even more preferably over 75 % sequence identity at the amino acid level and most preferably over 85 % sequence identity at the amino acid level.

[0059] The invention in particular concerns a method for prevention or treatment of a LXR receptor protein or LXR receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention wherein the prevention or treatment is directly or indirectly accomplished through the binding of a compound according to the invention to the LXR receptor protein or to the LXR receptor protein homologue.

[0060] The term mediated herein means that the physiological pathway in which the LXR receptor protein acts is either directly or indirectly involved in the disease or condition to be treated or prevented. In the case where it is indirectly involved it could be that, e.g. modulating the activity of LXR by a compound according to the invention influences a parameter which has a beneficial effect on a disease or a condition. One such example is that modulation of LXR activity leads to decreased levels of serum cholesterol or certain lipoproteins which in turn have a beneficial effect on the prevention and treatment of atherosclerosis. Herein a condition is a physiological or phenotypic state which is desirably altered. One such example would be obesity which is not necessarily medically harmful but nonetheless a non desirable phenotypic condition. In a preferred embodiment of the invention the method for prevention or treatment of a LXR receptor protein mediated disease or condition is applied to a human. This may be male or female.

[0061] Pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in human is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition. In general, the compositions are administered in an amount of active agent of at least about 100 μg/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, doses is from about 100 μg/kg to about 5 mg/kg body weight, daily.

[0062] For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of active agent will be 0,1 mg/kg to 10 mg/kg and typically around 1 mg/kg.

[0063] By "therapeutically effective amount" is meant a symptom- alleviating or symptom -reducing amount, a cholesterol-reducing amount, a cholesterol absorption blocking amount, a protein and/or carbohydrate digestion-blocking amount and/or a de novo cholesterol biosynthesisblocking amount of a compound according to the invention.

[0064] Likewise, the invention concerns a method of treating in mammal a disease which is correlated with abnormal cholesterol, triglyceride, or bile acid levels or deposits comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention.

[0065] Accordingly, the compounds according to the invention may also be used as a method of prevention or treatment of mammalian atherosclerosis, gallstone disease, lipid disorders, Alzheimer's disease, skin disorders, obesity or cardiovascular disorders such as coronary heart disease or stroke.

[0066] The invention further concerns a method of blocking in a mammal the cholesterol absorption in the intestine in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention. The invention may also be used to treat obesity in humans.

[0067] The Liver X Receptor alpha is a prototypical type 2 nuclear receptor meaning that it activates genes upon binding to the promoter region of target genes in a heterodimeric fashion with Retinoid X Receptor. The relevant physiological ligands of LXR are oxysterols. The present compounds according to the invention have been demonstrated to have a high binding efficacy (binding coefficients measured as EC50 in the range 100 nM to 1500 nM) as well as agonistic and / or antagonistic properties. Consequently they may be applied to regulate genes that participate in bile acid, cholesterol and fatty acid homeostasis as well as other downstream regulated genes. Examples of such genes are but are not limited to lipid absorption, cholesterol biosynthesis, cholesterol transport or binding, bile acid transport or binding, proteolysis, amino acid metabolism, glucose biosynthesis, protein translation, electron transport, and hepatic fatty acid metabolism. LXR often functions *in vivo* as a heterodimer with the Retinoid X Receptor. Published LXR agonists such as the Tularik compound "TO901317" (See figure 5) are known to influence the regulation of various liver genes. Genes found to be regulated by TO901317 can be found in figure 6. Thus, the invention also concerns a method of modulating a gene whose expression is regulated by the LXR receptor in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention to said mammal.

[0068] A number of direct and indirect LXR target genes have been described whose regulated expression contribute to cholesterol homeostasis and lipogenesis. In this respect the direct regulation of Cyp7A, which was shown to be a direct target gene of LXR at least in the rodent lineage is an important aspect of cholesterol removal by increased metabolism of bile acids (Lehmann et al., *J Biol. Chem.* 272 (6) 3137-3140; 1007). Gupta et al. (*Biochem. Biophys. Res. Com.*, 293; 338-343, 2002) showed that LXR α regulation of Cyp7A is dominant over FXR inhibitory effects on Cyp7A transcription.

[0069] A key transcription factor that was also shown to be a direct target gene for the LXR receptor is SREBP-1C (Repa et al., *Genes and Development*, 14:2819-2830; 2000; Yoshikawa et al.; *Mol. Cell. Biol.* 21 (9) 2991-3000, 2001). SREBP-1C itself activates transcription of genes involved in cholesterol and fatty acid synthesis in liver but also other mammalian tissues. Some of the SREBP1c target genes involved in lipogenesis like FAS and SCD have shown to be additionally direct targets of the LXR receptors (Joseph et al.; *J Biol. Chem.* 2002 Mar 29;277(13):11019-25; Liang et al., *J Biol. Chem.* 2002 Mar 15;277(11):9520-8.).

[0070] Another gene that has been shown to be directly regulated by LXRs is the LPL gene, that codes for a key enzyme that is responsible for the hydrolysis of triglycerides in circulating lipoprotein, releasing free fatty acids to peripheral tissues. (Zhang et al. *J Biol. Chem.* 2001 Nov 16;276(46):43018-24.) This enzyme is believed to promote uptake of HDL cholesterol in liver, thereby promoting reverse cholesterol transport. A similar functional involvement in HDL clearance is described for the CETP gene product that facilitated the transfer of HDL cholesterol esters from plasma to the liver. LXR response elements were found in the CETP promoter and direct activation of this gene by LXR was demonstrated (Luo and Tall; *J Clin. Invest.* 2000 Feb;105(4):513-20.).

[0071] The regulated transport of cholesterol through biological membranes is an important mechanism in order to maintain cholesterol homeostasis. A pivotal role in these processes in multiple tissues like e.g. macrophages and intestinal mucosa cells is maintained by the ATPbinding cassette transporter proteins (ABC). ABCA1 and ABCG1 were identified as direct LXR target genes (Costet et al.; *J Biol. Chem.* 2000 Sep 8;275(36):28240-5) that mediate cholesterol efflux and prevent thereby e.g. generation of artherogenic plaques in macrophages (Singaraja et al. *J Clin. Invest.* 2002 Jul;110(1):35-42). Other ABC transporters like ABCG5 and ABCG8, primarily expressed in hepatocytes and enterocytes have also been reported to be directly responsive to LXR agonists (Repa et al., *J Biol. Chem.* 2002 May 24;277 (21):18793-800. Kennedy et al., *J Biol. Chem.* 2001 Oct 19;276(42):39438-47) and mediate the secretion of sterols from the liver and efflux of dietary sterols from the gut.

[0072] Apolipoproteins E, C-I, C-II, and C-IV, that fulfill important roles in lipoprotein/lipid homeostasis have also been shown to be direct targets of the LXR receptor (Laffitte et al., *Proc. Natl. Acad. Sci. U. S. A.* 2001 Jan 16;98(2): 507-12; Mak et al.; *J Biol. Chem.* 2002 May 24 [epub ahead of print]). These proteins have been found to be crucial components of chylomicrons, VLDL, IDL, and HDL and are among other things associated with hypertriglyceridemia and arteriosclerosis.

[0073] Recently the LXR α itself was shown to be regulated by both LXR receptors in human cell types including macrophages suggesting an autoregulatory amplification event in the response to LXR ligands which could e.g. lead to an enhanced stimulation of LXR target genes like e.g. ABCA1 (Bolten et al.; Mol Endocrinol. 2002 Mar;16(3):506-14.; Laffitte et al., Mol Cell Biol. 2001 Nov;21(22):7558-68; Whitney et al.; J Biol Chem. 2001 Nov 23;276(47):43509-15).

[0074] Besides the important function of LXR receptors in tissues like liver and macrophages it has recently been reported that that stimulation of epidermal differentiation is mediated by Liver X receptors in murine epidermis. Differentiation marker genes like involucrin, loricin and profilaggrin have been shown to be upregulated upon LXR ligand treatment (Kömüves et al.; J Invest Dermatol. 2002 Jan;118(1):25-34.).

[0075] Another recent report describes the regulation of cholesterol homeostasis (primarily the regulation of ABCA1, ABCG1 and SREBP-1C) by the LXR receptors in the central nervous system suggesting that LXR may prove beneficial in the treatment of CNS diseases such as Alzheimer's and Niemann-Pick disease that are known to be accompanied by dysregulation of cholesterol balance (Whitney et al.; Mol Endocrinol. 2002 Jun;16(6):1378-85).

[0076] Therefore one important embodiment the invention concerns are methods that enhances or suppresses amongst other today yet unknown LXR target genes the above mentioned genes and the associated biological processes and pathways through LXR compounds that are subject of this invention.

[0077] The compounds according to the invention may be used as medicaments, in particular for the manufacture of a medicament for the prevention or treatment of a LXR receptor protein or LXR receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to the invention to the LXR receptor protein or LXR receptor protein homologue.

[0078] These pharmaceutical compositions contain 0,1 % to 99,5 % of the compound according to the invention, more particularly 0,5 % to 90 % of the compound according to the invention in combination with a pharmaceutically acceptable carrier.

[0079] The invention concerns also the use of a compound according to the invention for the manufacture of a medicament for the prevention or treatment of a LXR receptor protein mediated disease or condition wherein the mammal described above is a human. The medicament may be used for regulating the cholesterol transport system, for regulating levels of cholesterol, triglyceride, and/or bile acid in a mammal preferentially a human by activating the LXR receptor. The medicament may be used for the treatment of atherosclerosis, gallstone disease, lipid disorders, Alzheimer's disease, skin disorders, obesity or a cardiovascular disorder.

[0080] The further concerns the use of a compound according to the invention for the manufacture of a medicament capable for blocking in a mammal, preferentially a human the cholesterol absorption in the intestine. Further the claimed compound may be used for the manufacture of a medicament for treating obesity in humans and for modulating a gene whose expression is regulated by the LXR receptor (see details above and figures).

[0081] The present invention shall now be further illustrated based on the following examples without being limited thereto. In the accompanying sequence protocol and the figures:

SEQ ID NO. 1 shows protein sequence of the LRX alpha protein a portion of which was used for cloning as described in the examples,

SEQ ID NO. 2 shows the mRNA sequence of the LRX alpha protein,

SEQ ID NO. 3 shows the protein sequence of TIF2 (Acc. No: XM_011633 RefSeq DB),

SEQ ID NO. 4 shows the respective mRNA sequence corresponding to the TIF2 protein,

SEQ ID NO 5 shows the protein sequence of the LXR beta protein a portion of which was used for cloning as described in examples,

SEQ ID NO 6 shows the mRNA sequence of the LXR beta protein,

SEQ ID NO 7 shows the sequence of primer (a) used in Example 1

SEQ ID NO 8 shows the sequence of primer (b) used in Example 1.

[0082] Fig. 1 shows the synthesis of the compounds according to the invention as also described in Example 2.

[0083] Fig. 2 shows the measurement parameters employed by the Wallace VICTOR2V™ Multilabel Counter which was used for measuring the EC₅₀ values

[0084] Fig. 3 A shows SEQ ID NO. 1 which is the protein sequence of the LRX alpha protein a portion of which was used for cloning as described in the examples. Figure 3 B shows SEQ ID NO. 2 which is the mRNA sequence of the

LRX alpha protein. Figure 3 C shows SEQ ID NO. 3 which is the protein sequence of TIF2 (Acc. No: XM_011633 RefSeq DB), Figure 3 D shows SEQ ID NO. 4 which is the respective mRNA sequence corresponding to the TIF2 protein. Figure 3 E shows SEQ ID NO 5 which is the protein sequence of the LXR beta protein a portion of which was used for cloning as described in examples. Figure 3 F shows SEQ ID NO 6 which is the mRNA sequence of the LXR beta protein.

[0084] Fig. 4 shows the internal molecular name used by the applicant (MOLNAME) as well as the corresponding structures of preferred compounds according to the invention. The figure further shows their respective EC₅₀ values (EC50 AVG) as established according to the experiment 1 in multiple experiments (see above), as well as their respective average efficacy (% activity relative to 22-(R)-hydroxycholesterol control agonist).

[0085] Figure 5 shows various known LXR ligands. It is apparent from their structures that the inventors have identified novel compounds which are structurally not related to these known ligands.

[0086] Figure 6 shows various genes that have been found to be regulated through binding of an LXR agonist to the LXR protein.

[0087] Figure 7 shows a dose-dependent transactivation (EC50 ~ 3 µM) by LN0000007465 of the luciferase reporter gene via LXR alpha.

[0088] Figure 8 shows (A) Analysis of mRNA content of the indicated genes in total RNA isolated from THP-1 cells treated for 24 hours with 2, 10 or 25 µM of LN0000006500 or 10 µM of the Tularik compound (T0901317). (B) Analysis of mRNA content for the indicated genes in total RNA from HepG2 cells treated for 24 hours with 2, 10 or 25 µM of LN0000006500 or 10 µM of the Tularik compound (T0901317).

[0089] Figure 9 shows the dose dependent transactivation by LN0000006500 of the pFR-luc reporter gene in CHO cells via Gal4 LBD-fusion constructs derived from LXRa- or LXRb. Concentrations of the compound administered (µM) and RLU's determined from extracts of cells are indicated.

[0090] Figure 10 shows the analysis of total cholesterol from supernatants of cultivated THP-1 cells incubated without or with ApoA1 and ApoA1 plus 10 µM of the compounds Tularik (T0901317) or LN0000006500, LN0000006662, LN0000006671 or LN0000006672 as indicated.

EXAMPLES

EXAMPLE 1:

[0091] In vitro screening for compounds which influence LXR binding to coactivators. For screening purposes a GST and 6 x His fusion of the LBD (from amino acids 155 of hLXRalpha to 447) of human LXRalpha was constructed by first cloning a Gateway cassette (Invitrogen) in frame into the Sma I site of the pAGHLT Polylinker (Pharmingen). Then a PCR fragment specifically amplified from human liver cDNA was cloned into the resulting pACGHLT-GW following the manufacturers instructions for Gateway cloning (Invitrogen) to yield pACGHLT-GW-hLXRalphaLBD.

Primers used for amplification were: primer (a)
 GGGGACAAGTTGTACAAAAAAGCAGGCTCGCTTCGCAAATGCCGTAG (SEQ ID NO 7), and primer (b)
 GGGGACCACTTGTACAAGAAAGCTGGTCCCCTCTCAGTCTGTTCCACTT (SEQ ID NO 8).

[0092] 100 % sequence integrity of all recombinant products was verified by sequencing. Recombinant Baculovirus was constructed from pACGHLT-GW-hLXRalphaLBD using the Pharmingen Baculovirus Expression vector system according to instructions of the manufacturer. Monolayer cultures of SF9 cells were infected by the virus as recommended by Pharmingen or 200ml cultures of 1 x 10⁶ cells/ml grown in 2 liter Erlenmeyer flasks on an orbital shaker at 30 rpm were infected by 10ml of same virus stock. In both cases cells were harvested 3 days after infection. All cell growth was performed in Gibco SF900 II with Glutamine (Invitrogen) medium without serum supplementation at 28°C. Since SF9 cells contain significant amounts of endogenous GST, purification was performed via His and not via GST affinity chromatography. To this end instructions of Pharmingen for purification of recombinant His tagged proteins from SF9 cells were followed with the following modifications: All detergents were omitted from the buffers and cells were lysed on ice by 5 subsequent sonication pulses using a sonicator needle at maximum power.

[0093] All eluates were dialyzed against 20 mM Tris/HCl pH 6,8, 300 mM KCl; 5 mM MgCl₂; 1 mM DTT; 0,2 mM

PMSF; 10% Glycerol. A typical dialyzed eluate fraction contained the fusion protein at a purity of more than 80%. Total protein concentration was 0,1-0,3 mg/ml.

[0094] For *E. coli* expression of a NR coactivator, pDest17-hTif2BD expressing a NR interaction domain from amino acids 548-878 of human Tif2 (Acc. No: XM_011633 RefSeq) tagged by 6 N-terminal His residues was constructed. Therefore, a PCR fragment specifically amplified from human liver cDNA was subcloned into pDest 17 (Invitrogen) following the manufacturers instructions for Gateway cloning (Invitrogen). Primers used for Amplification were: primer (a)

10 **GGGGACAAGTTGTACAAAAAAGCAGGCTCGTTAGGGTCATCGTTGGCTTCACC**

and

primer

(b)

15 **GGGGACCACTTGTACAAGAAAGCTGGGTCTCAAAGTTGCCCTGGTCGTGGTTA**

[0095] For *E. coli* expression plasmid DNA was transformed into chemically competent *E. coli* BL21 (Invitrogen, USA) and cells were grown to an OD600 of 0.4-0.7 before expression was induced by addition of 0,5 mM IPTG according instructions of the manufacturer (Invitrogen). After induction for 8 hours at 30°C cells were harvested by centrifugation for 10 minutes at 5000 x g. Fusion proteins were affinity purified using Ni-NTA Agarose (QIAGEN) according to the instructions of the manufacturer. Recombinant Tif2 construct was dialyzed against 20 mM Tris/HCl pH 7.9; 60 mM KCl; 5 mM MgCl₂; 1 mM DTT, 0,2 mM PMSF; 10% glycerol. A typical dialyzed eluate fraction contained the fusion protein at a purity of more than 80%. Total protein concentration was 0,1-0,3 mg/ml.

[0096] The TIF2 fragment was subsequently biotinylated by addition of 5-40µl/ml Tif2 fraction of a Biotinamidocaproate N-Hydroxysuccinimide-ester (Sigma) solution (20 mg/ml in DMSO). Overhead rotating samples were incubated for 2 hours at room temperature. Unincorporated label was then separated using G25 Gel filtration chromatography (Pharmacia Biotech, Sweden). Protein containing fractions from the column were pooled and tested for activity in the assay as described below.

[0097] For screening of compound libraries as provided for by the methods shown below in the examples for substances which influence the LXR/Tif 2 interaction, the Perkin Elmer LANCE technology was applied. This method relies on the binding dependent energy transfer from a donor to an acceptor fluorophore attached to the binding partners of interest. For ease of handling and reduction of background from compound fluorescence LANCE technology makes use of generic fluorophore labels and time resolved detection (for detailed description see Hemmilä I, Blomberg K and Hurskainen P, Time-resolved resonance energy transfer (TR-FRET) principle in LANCE, Abstract of Papers Presented at the 3 rd Annual Conference of the Society for Biomolecular Screening, Sep., California (1997))

[0098] For screening, 20-200 ng of biotinylated Tif 2 fragment and 10-200 ng of GST-LXR fragment were combined with 0.5-2 nM LANCE Eu-(W1024) labelled anti-GST antibody (Perkin Elmer) and 0,1-0,5µg of highly fluorescent APC-labelled streptavidin (Perkin Elmer, AD0059) in the presence of 50µM of individual compounds to be screened in a total volume of 25 µl of 20 mM Tris /HCl pH 6,8; 300 mM KCl; 5 mM MgCl₂; 100-1000 ng/µl/ BSA DMSO content of the samples was kept below 4%. Samples were incubated for a minimum of 60 minutes in the dark at room temperature in FIA-Plates black 384well med. binding (Greiner).

[0099] The LANCE signal was detected by a Perkin Elmer VICTOR2V™ Multilabel Counter applying the detection parameters listed in Fig. 2. The results were visualized by plotting the ratio between the emitted light at 665 nm and at 615 nm. For every batch of recombinant proteins amount of proteins, including BSA and labeling reagents giving the most sensitive detection of hits was determined individually by analysis of dose response curves for 22R Hydroxycholesterol and TO 901317

50 EXAMPLE 2:

[0100] Experimental procedure for the preparation of the compounds according to the invention.

o-AZIDOBENZOIC ACID SYNTHESIS (2)

[0101] The anthranilic acid (1, 1 eq., 0.5-1 M) was suspended in 6 M HCl, containing enough AcOH (0-20% dependent upon the anthranilic acid) to facilitate dissolution of the anthranilic acid and/or the intermediate diazonium salt, and cooled to 0 °C. NaNO₂ (1.1 eq., 1.3-2.5 M) dissolved in H₂O was added to the anthranilic acid solution at a rate such

that the temperature of the reaction solution remained below 5 °C. The resulting homogeneous solution of the diazonium salt was slowly filtered through a sintered glass funnel into a solution of NaN₃ (1.1 eq., 0.7-1.1 M) and NaOAc (12 eq.) in H₂O. The reaction mixture was stirred/shaken for 30-60 min following cessation of vigorous N₂ evolution. Following acidification of the reaction mixture to pH 1 with concentrated HCl, the mixture was cooled to 0 °C to encourage complete precipitation of the *o*-azidobenzoic acid. The precipitate was collected by filtration and washed with 6 M HCl (2x) and H₂O (2x). The *o*-azidobenzoic acid product (2) was dried in *vacuo* (500 mtorr, 30 °C).

ACYLATION OF HYDROXYMETHYL RESIN (4)

[0102] To hydroxymethyl resin (1.0 eq., 1.3 mmol/g) and the *o*-azidobenzoic acid (1, 2.5 eq.) was added DMF (to give 400 mM *o*-azidobenzoic acid), CsCO₃ (2.0 eq.) and KI (2.0 eq.). Following agitation of the reaction mixture for 36-48 h, the resin-bound *o*-azidobenzoic acid (4) was washed with MeOH (2 cycles), CH₂Cl₂ (3 cycles), MeOH (3 cycles), DMF (3 cycles), MeOH (3 cycles) and CH₂Cl₂ (3 cycles), and dried *in vacuo*.

15 AZA-WITTIG FORMATION (5)

[0103] To the resin-bound *o*-azidobenzoic acid (4, 1.0 eq.) was added a solution of PPh₃ (THF, 500 mM, 5.0 eq.). After 6 h, the resin was washed with 3 cycles of the following: THF (3 cycles), toluene (3 cycles), CH₂Cl₂ (3 cycles) and hexanes (3 cycles). Followed by drying *in vacuo* to afford resin bound iminophosphorane (5)

20 CARBODIIMIDE FORMATION (6)

[0104] To the resin-bound iminophosphorane (5, 1 eq.) was added isocyanate (9, 5 eq., 450 mM) dissolved in CICH₂CH₂Cl. The compounds were shaken at ambient temperature for 16 h, washed with 3 cycles of the following: THF (3 cycles), toluene (3 cycles), CH₂Cl₂ (3 cycles) and hexanes (3 cycles), and dried *in vacuo* to afford carbodiimide (6).

GUANIDINE FORMATION / CYCLIZATION

[0105] To the carbodiimide functionalized resin (6) was added secondary amine (10, 0.6 eq., 500 mM) dissolved in CICH₂CH₂Cl. The reaction mixture was heated to 50 °C in an incubator for 12-72 h to afford 2-aminoquinazoline (8).

[0106] All of the final products were analyzed by HPLC using mass and an Evaporative Light Scattering Detector (ELSD) detection to determine purity and identity.

[0107] One skilled in the art will be able to arrive at the compounds claimed herein making use of said protocol.

35 EXAMPLE 3:

[0108] This example illustrates that a compound according to the invention (experiments shown were done with MOLSTRUCTURE LN 0000007465 (see figures 4 for structural formula)) can mediate transactivation of LXR mediated transcription in HEK293 cells.

[0109] HEK293 cells were grown in 48 well plates and co-transfected with the pTRexDest30 (Invitrogen) derivatives pTRexDest30-hLXR α , pTRexDest30-hRXR α and the pGL2promoter (Promega) derivative pGL2promoter-LXRRE (each 300 ng of plasmid DNA). The full length human LXR (accession U68233) and the full length human RXR α (accession P19793) were cloned into the pTRexDest30 applying the manufacturer protocols for the GatewayTM system (Invitrogen).

[0110] The LXR response elements (LXRRE) were (upper case and underlined) 5' CcctTGGTCActcaAGTTCAagtgatgatagaattcgatccTGGTCActcaAGTTCAagtgA 3' (SEQ ID NO. 5) derived from the rat Cyp7a promoter (Laffite et al., 2001, PNAS 98, pp 507). Luciferase reporter activity was measured in triplicates from extracts of cells after incubating cells in culture medium (DMEM [Gibco-BRL] + 10% FCS [PAA laboratories]) for 16 hours (5% CO₂, 37 °C) containing 0.5% DMSO (control) or 0.5% DMSO with increasing concentrations of LN0000007465.

[0111] A dose-dependent transactivation (EC50 ~ 3 μ M) of the reporter gene by LXR α was observed (Fig. 7).

Example 4:

[0112] This example shows that described compounds can increase the abundance of mRNA of target genes for the LXR proteins in THP-1 cells treated with TPA.

[0113] THP-1 (3x10⁵ cells per dish) cells were seeded in 24 well dishes in 3 ml modified RPMI-1640 medium (ATTC,

Cat.No. 30-2001) containing 10%FCS (GIBCO) and 100nM TPA and cultivated at 37°C in 5% CO₂ for 48 hours. The medium was then removed and replaced with medium containing 10% charcoal/stripped FBS (Hyclone) and incubated with LN0000006500 at 2, 10 or 25 µM concentration or Tularik (T0901317) at 10 µM for 24 hours as indicated in Fig 8A as an example. HepG2 (4,5x10⁵ cells per dish) were seeded in 24 well dishes in 3 ml DMEM Medium containing 10%FCS (GIBCO) and cultivated at 37°C in 5% CO₂ for 48 hours as indicated in Fig 8B.

[0114] After incubation for 24 hours in presence of compound, total RNA was isolated from the cells using a Quiagen RNAeasy kit (Quiagen) according to the manufacturers protocol. The RNA was then reverse transcribed and analyzed by TaqMan Analysis using kits and equipment from Perkin-Elmer known to those knowledgeable in the field.

[0115] The fold change of mRNA abundance of compound treated versus DMSO treated as a control is shown in Figure 8A and B for several analyzed target genes indicated in Figure 8A and B.

Example 5:

[0116] This example shows that described compounds can selectively enhance transcription mediated by the LBD's of the respective nuclear receptors LXRa and LXRB.

[0117] CHO cells (1x10⁵ cells 96well plate) were co-transfected (Lipofectamine 2000 GIBCO) with pFR-luc (Stratagene) as a reporter gene construct and pCMV-AD derivatives containing the LXRa or LXRB ligand binding domains, which were cloned via the gateway system (GIBCO) described in Example 1, in order to express Gal4DBD-LXRa or Gal4DBD-LXRB fusion proteins.

[0118] Cells were grown in DMEM containing 10%FCS at 37°C in 5% humidified CO₂ for 16h in presence of 0,05% DMSO vehicle or 0,032 to 50 µM LN0000006500 in vehicle (as indicated in Fig.9). Luciferase activity was determined from aliquots of extracts prepared from cells following standard luciferase assay kits and protocols from Promega.

Example 6:

[0119] This example shows that described compounds at 10 µM concentration for 24 hours can increase the reverse cholesterol transport in THP-1 cells that were treated with TPA.

[0120] THP-1 (1x10⁶ cells per dish) cells were seeded in 6 well dishes in 3ml modified RPMI1640 medium (ATTC, Cat.No. 30-2001) containing 10%FCS (GIBCO) and 100nM TPA and cultivated at 37°C in 5% CO₂ for 72 hours. The medium was then removed and replaced with fresh medium containing 100 nM TPA and 0,15 % BSA. After 24 h incubation the cells were washed in PBS and 1,5 ml of fresh medium containing either 0,1% DMSO alone or 0,1% DMSO together with 40µg/ml ApoA1 (Calbiochem) or 40µg/ml ApoA1 plus the in Fig. 10 as an example indicated compounds Tularik (T0901317), LN0000006500, LN0000006662, LN0000006671, LN0000006674 at 10 µM.

[0121] After incubation for 24 hours, total cholesterol was determined from cell supernatant in each of the wells using an enzymatic assay with fluorescence read-out for the determination of cholesterol (Amplex Red Cholesterol Assay Kit (A-12213). The fluorescence readout per mg of total protein content as determined from cells that were present in the respective well are shown in Figure 9 as an example.

40

45

50

55

SEQUENCE LISTING

5 <110> LION bioscience
<120> LXR Nuclear receptor binding compounds
<130> FB11712
<160> 8
<170> PatentIn version 3.1

10 <210> 1
<211> 52
<212> DNA
<213> Homo sapiens

15 <400> 1
ggggaccact ttgtacaaga aagctgggtc ccattctcag tctgttccac tt 52

20 <210> 2
<211> 1344
<212> DNA
<213> Homo sapiens

25 <400> 2
atgtccttgc ggctggggc ccctgtgcct gacattcctc ctgactctgc ggtggagctg
tggaaagccag ggcacacagga tgcaaggcago caggcccagg gaggcagcag ctgcattcctc 60
agagaggaag ccaggatgcc ccactctgct ggggtactg caggggtggg gctggaggct
25 gcagagccca cagccctgct caccaggca gagccccctt cagaaccac agagatccgt
ccacaaaaagc gaaaaaaaggc gccagccccc aaaatgctgg ggaacgagct atgcagcgtg 120
30 tgtggggaca aggcctcggg cttccactac aatgttctga gctgcgaggg ctgcaaggga
ttcttccgcc gcagcgtcat caagggagcg cactacatct gccacagtgg cggccactgc 180
cccatggaca cctacatgcg tcgcaagtgc caggagtgc ggctcgaa atgcgtcag
35 gctggcatgc gggaggagtg tgtcctgtca gaagaacaga tccgcctgaa gaaactgaag
cgcaagagg aggaacaggc tcatgccaca tccttgcctt ccaggcggttc ctcacccccc 240
caaattcctgc cccagctcag cccggaaacaa ctgggcatga tcgagaagct cgtcgtcag
40 cagcaacagt gtaaccggcg ctccctttct gaccggcttc gagtcacgccc ttggcccatg
gcaccagatc cccatagccg ggaggcccgt cagcagcgct ttgcccactt cactgagctg
45 gccatcgatc ctgtgcagga gatagttgac tttgctaaac agctacccgg ctgcctgcag
ctcagccggg aggaccagat tgccctgctg aagacctctg cgatcgaggt gatgcttctg
gagacatctc ggaggtacaa ccctggaggt gagagtatca ctttcctcaa ggatttcagt
50 tataaccggg aagactttgc caaagcaggg ctgcaagtgg aattcatcaa cccatcttc
gagttctcca gggccatgaa tgagctgaa ctcaatgatg ccgagttgc ctgcatt
gctatcagca tcttcctgc agaccggccc aacgtgcagg accagctcca ggtggagagg
55 ctgcagcaca catatgtgga agccctgcat gcctacgtct ccatccacca tccccatgac 1020
ctgcagcaca catatgtgga agccctgcat gcctacgtct ccatccacca tccccatgac 1080
ctgcagcaca catatgtgga agccctgcat gcctacgtct ccatccacca tccccatgac 1140

EP 1 407 774 A1

EP 1 407 774 A1

450 455 460

5 Lys Asp Ser Thr Gly Ser Leu Pro Gly Ser Gly Ser Thr His Gly Thr
465 470 475 480

10 Ser Leu Lys Glu Lys His Lys Ile Leu His Arg Leu Leu Gln Asp Ser
485 490 495

15 Ser Ser Pro Val Asp Leu Ala Lys Leu Thr Ala Glu Ala Thr Gly Lys
500 505 510

20 Asp Leu Ser Gln Glu Ser Ser Thr Ala Pro Gly Ser Glu Val Thr
515 520 525

25 Ile Lys Gln Glu Pro Val Ser Pro Lys Lys Glu Asn Ala Leu Leu
530 535 540

30 Arg Tyr Leu Leu Asp Lys Asp Asp Thr Lys Asp Ile Gly Leu Pro Glu
545 550 555 560

35 Ile Thr Pro Lys Leu Glu Arg Leu Asp Ser Lys Thr Asp Pro Ala Ser
565 570 575

40 Asn Thr Lys Leu Ile Ala Met Lys Thr Glu Lys Glu Glu Met Ser Phe
580 585 590

45 Glu Pro Gly Asp Gln Pro Gly Ser Glu Leu Asp Asn Leu Glu Glu Ile
595 600 605

50 Leu Asp Asp Leu Gln Asn Ser Gln Leu Pro Gln Leu Phe Pro Asp Thr
610 615 620

55 Arg Pro Gly Ala Pro Ala Gly Ser Val Asp Lys Gln Ala Ile Ile Asn
625 630 635 640

60 Asp Leu Met Gln Leu Thr Ala Glu Asn Ser Pro Val Thr Pro Val Gly
645 650 655

65 Ala Gln Lys Thr Ala Leu Arg Ile Ser Gln Ser Thr Phe Asn Asn Pro
660 665 670

70 Arg Pro Gly Gln Leu Gly Arg Leu Leu Pro Asn Gln Asn Leu Pro Leu
675 680 685

75 Asp Ile Thr Leu Gln Ser Pro Thr Gly Ala Gly Pro Phe Pro Pro Ile
690 695 700

EP 1 407 774 A1

Arg Asn Ser Ser Pro Tyr Ser Val Ile Pro Gln Pro Gly Met Met Gly
705 710 715 720

5 Asn Gln Gly Met Ile Gly Asn Gln Gly Asn Leu Gly Asn Ser Ser Thr
725 730 735

10 Gly Met Ile Gly Asn Ser Ala Ser Arg Pro Thr Met Pro Ser Gly Glu
740 745 750

15 Trp Ala Pro Gln Ser Ser Ala Val Arg Val Thr Cys Ala Ala Thr Thr
755 760

20 Ser Ala Met Asn Arg Pro Val Gln Gly Gly Met Ile Arg Asn Pro Ala
770 775 780

25 Ala Ser Ile Pro Met Arg Pro Ser Ser Gln Pro Gly Gln Arg Gln Thr
785 790 795 800

Leu Gln Ser Gln Val Met Asn Ile Gly Pro Ser Glu Leu Glu Met Asn
805 810 815

30 Met Gly Gly Pro Gln Tyr Ser Gln Gln Ala Pro Pro Asn Gln Thr
820 825 830

35 Ala Pro Trp Pro Glu Ser Ile Leu Pro Ile Asp Gln Ala Ser Phe Ala
835 840 845

Ser Gln Asn Arg Gln Pro Phe Gly Ser Ser Pro Asp Asp Leu Leu Cys
850 855 860

40 Pro His Pro Ala Ala Glu Ser Pro Ser Asp Glu Gly Ala Leu Leu Asp
865 870 875 880

45 Gln Leu Tyr Leu Ala Leu Arg Asn Phe Asp Gly Leu Glu Glu Ile Asp
885 890 895

Arg Ala Leu Gly Ile Pro Glu Leu Val Ser Gln Ser Gln Ala Val Asp
900 905 910

50 Pro Glu Gln Phe Ser Ser Gln Asp Ser Asn Ile Met Leu Glu Gln Lys
915 920 925

55 Ala Pro Val Phe Pro Gln Gln Tyr Ala Ser Gln Ala Gln Met Ala Gln
930 935 940

Gly Ser Tyr Ser Pro Met Gln Asp Pro Asn Phe His Thr Met Gly Gln
945 950 955 960

5 Arg Pro Ser Tyr Ala Thr Leu Arg Met Gln Pro Arg Pro Gly Leu Arg
 965 970 975

Pro Thr Gly Leu Val Gln Asn Gln Pro Asn Gln Leu Arg Leu Gln Leu
 980 985 990

10 Gln His Arg Leu Gln Ala Gln Gln Asn Arg Gln Pro Leu Met Asn Gln
 995 1000 1005

15 Ile Ser Asn Val Ser Asn Val Asn Leu Thr Leu Arg Pro Gly Val
 1010 1015 1020

Pro Thr Gln Ala Pro Ile Asn Ala Gln Met Leu Ala Gln Arg Gln
 1025 1030 1035

20 Arg Glu Ile Leu Asn Gln His Leu Arg Gln Arg Gln Met His Gln
 1040 1045 1050

25 Gln Gln Gln Val Gln Gln Arg Thr Leu Met Met Arg Gly Gln Gly
 1055 1060 1065

Leu Asn Met Thr Pro Ser Met Val Ala Pro Ser Gly Met Pro Ala
 1070 1075 1080

30 Thr Met Ser Asn Pro Arg Ile Pro Gln Ala Asn Ala Gln Gln Phe
 1085 1090 1095

35 Pro Phe Pro Pro Asn Tyr Gly Ile Ser Gln Gln Pro Asp Pro Gly
 1100 1105 1110

Phe Thr Gly Ala Thr Thr Pro Gln Ser Pro Leu Met Ser Pro Arg
 1115 1120 1125

40 Met Ala His Thr Gln Ser Pro Met Met Gln Gln Ser Gln Ala Asn
 1130 1135 1140

45 Pro Ala Tyr Gln Ala Pro Ser Asp Ile Asn Gly Trp Ala Gln Gly
 1145 1150 1155

Asn Met Gly Gly Asn Ser Met Phe Ser Gln Gln Ser Pro Pro His
 1160 1165 1170

50 Phe Gly Gln Gln Ala Asn Thr Ser Met Tyr Ser Asn Asn Met Asn
 1175 1180 1185

55 Ile Asn Val Ser Met Ala Thr Asn Thr Gly Gly Met Ser Ser Met
 1190 1195 1200

5 Asn Gln Met Thr Gly Gln Ile Ser Met Thr Ser Val Thr Ser Val
 1205 1210 1215

10 Pro Thr Ser Gly Leu Ser Ser Met Gly Pro Glu Gln Val Asn Asp
 1220 1225 1230

15 Pro Ala Leu Arg Gly Gly Asn Leu Phe Pro Asn Gln Leu Pro Gly
 1235 1240 1245

20 Met Asp Met Ile Lys Gln Glu Gly Asp Thr Thr Arg Lys Tyr Cys
 1250 1255 1260

<210> 4
<211> 6158
<212> DNA
20 <213> Homo sapiens

25 <400> 4
ggcggccgca gcctcggcta cagttcggc ggcgaaggc agcggccgacg gcagccggca 60
cctgacggcg tgaccgaccc gagccgattt ctcttggatt tggctacaca cttatagatc 120
ttctgcactg tttacaggca cagttgctga tatgtgttca agatgagtgg gatgggagaa 180
aataacctctg acccctccag ggcagagaca agaaagcgcga aggaatgtcc tgaccaactt 240
30 ggacccagcc ccaaaaaggaa cactaaaaaa cgtaatcgtg aacaggaaaa taaatatata 300
gaagaacttg cagagttgat tttgcaaattttaatgata tagacaactt taacttcaaa 360
cctgacaaat gtgcaatctt aaaagaaaact gtgaagcaaa ttcgtcagat caaagaacaa 420
35 gagaaagcag cagctgccaa catagatgaa gtgcagaagt cagatgtatc ctctacaggg 480
cagggtgtca tcgacaagga tgcgtgggg cctatgatgc ttgaggccct tggatgggttc 540
ttctttgttag tgaacctgga aggcaacgtt gtgtttgtt cagagaatgt gacacagtat 600
40 ctaaggatata accaagaaga gctgatgaac aaaagtgtat atagcatctt gcatgttggg 660
gaccacacgg aatttgcataa aacacctgctg ccaaagtcta tagttaatg ggggatcttgc 720
gtctggcgaa cctccgagggc ggaacagccaa taccttcaat tgcggatgc tggtaaaacc 780
45 tttacctgat tcagaagagg agggcatgaa taaccaggaa gctcatcaga aatatgaaac 840
tatgcagtgc ttgcgtgtct ctcaacccaa gtccatcaaa gaagaaggag aagatttgca 900
gtcctgctt atttgcgtgg caagaagagt tcccatgaaag gaaagaccag ttcttccctc 960
50 atcagaaaat tttactactc gccaggatct ccaaggcaag atcacgtctc tggataccag 1020
caccatgaga gcagccatgaa aaccaggctg ggaggacctg gtaagaaggt gtattcagaa 1080
gttccatgca cagcatgaa gagaatctgt gtcctatgct aagaggcatc atcatgaaat 1140
55 actgagacaa ggattggcat tcagtcataat ctatcgat ttcgtctg atggcactct 1200

5	tgttgctgca caaacgaaga gcaaactcat ccgttctag actactaatg aacctaact	1260
	tgtatatct ttacatatgc ttcacagaga gcagaatgtg tgtgtatga atccggatct	1320
	gactggacaa acgatgggaa agccactgaa tccaatttagc tctaacagcc ctgcccata	1380
10	ggccctgtgc agtggaaacc caggtcagga catgaccctc agtagcaata taaattttcc	1440
	cataaatggc ccaaaggaaac aaatgggcat gcccatggc aggttggtg gttctggggg	1500
	aatgaaccat gtgtcaggca tgcaagcaac cactccttag ggtagtaact atgcactcaa	1560
	aatgaacagc ccctcacaaa gcagccctgg catgaatcca ggacagccca cctccatgct	1620
15	ttcaccaagg catcgcatga gccctggagt ggctggcagc cctcgaatcc cacccagtca	1680
	gtttccctt gcaggaagct tgcattcccc tgtggagtt tgcagcagca cagggaaatag	1740
	ccatagttt accaacagct ccctcaatgc acttcaggcc ctcagcgagg ggcacgggg	1800
20	ctcattaggg tcatcggttgg cttcaccaga cctaaaaatg ggcaatttgc aaaactcccc	1860
	agttaatatg aatccctcccc cactcagcaa gatggaaagc ttggactcaa aagactgttt	1920
	tggactatat gggagccct ctgaaggtac aactggacaa gcagagagca gctgccatcc	1980
25	tggagagcaa aaggaaacaa atgaccccaa cctgcccccg gecgtgagca gtgagagagc	2040
	tgacgggcag agcagactgc atgacagcaa agggcagacc aaactcctgc agctgctgac	2100
	caccaaatct gatcagatgg agccctcgcc cttagccagc tctttgtcgg atacaaacaa	2160
30	agactccaca ggtagcttgc ctgggtctgg gtctacacat ggaacctcgc tcaaggagaa	2220
	gcataaaatt ttgcacagac tcttgcagga cagcagttcc cctgtggact tggccaagtt	2280
	aacagcagaa gccacaggca aagacctgag ccaggagtcc agcagcacag ctcctggatc	2340
35	agaagtgact attaaacaag agccggtag ccccaagaag aaagagaatg cactacttcg	2400
	ctatttgcta gataaagatg atactaaaga tattggtttcc cagaaataaa ccccaaaact	2460
	tgagagactg gacagtaaga cagatcctgc cagtaacaca aaattaatag caatgaaaac	2520
40	tgagaaggag gagatgagct ttgagcttgg tgaccgcctt ggcagtgagc tggacaactt	2580
	ggaggagatt ttggatgatt tgcagaatag tcaattacca cagctttcc cagacacgag	2640
	gccaggcgcc cctgctggat cagttgacaa gcaagccatc atcaatgacc tcatgcaact	2700
45	cacagctgaa aacagccctg tcacacctgt tggagccag aaaacagcac tgcgaatttc	2760
	acagagcact tttataacc caccgaccagg gcaactggc agtttattgc caaaccagaa	2820
	tttaccactt gacatcacat tgcaaagccc aactggtgct ggaccttcc caccaatcag	2880
50	aaacagtagt ccctactcag tgatacctca gccaggaatg atggtaatc aagggatgat	2940
	aggaaaccaa ggaaatttag ggaacagtag cacaggaatg attgtaaca gtgcttctcg	3000
	gcctactatg ccatctggag aatggcacc gcagagttcg gctgtgagag tcacctgtgc	3060

5	tgctaccacc agtccatga accggccagt ccaaggaggt atgattcga acccagcagc	3120
	cagcatcccc atgaggccca gcagccagcc tggccaaaga cagacgcttc agtctcagg	3180
	catgaatata gggccatctg aatttagagat gaacatgggg ggacctcagt atagccaaca	3240
10	acaagctctt ccaaattcaga ctgccccatg gcctgaaagc atcctgccta tagaccaggc	3300
	gtctttgcc agccaaaaca ggcagccatt tggcagttct ccagatgact tgctatgtcc	3360
	acatcctgca gctgagtctc cgagtgtatga gggagctctc ctggaccagc tgtatctggc	3420
	cttgcggaat tttgtatggcc tggaggagat tgatagagcc ttaggaatac ccgaactgg	3480
15	cagccagagc caagcagtag atccagaaca gttctcaagt caggattcca acatcatgct	3540
	ggagcagaag ggcgcgttt tcccacagca gtatgcattc caggcacaaa tggcccgagg	3600
	tagtattct cccatgcaag atccaaactt tcacaccatg ggacagcggc ctagttatgc	3660
20	cacactccgt atgcagccca gaccgggcct caggcccacg ggcctagtgc agaaccagcc	3720
	aaatcaacta agacttcaac ttcaagcatcg cctccaagca cagcagaatc gccagccact	3780
	tatgaatcaa atcagcaatg tttcaatgt gaacttgact ctgaggcctg gagtaccaac	3840
25	acaggcacct attaatgcac agatgctggc ccagagacag agggaaatcc tgaaccagca	3900
	tcttcgacag agacaaatgc atcagcaaca gcaagttcag caacgaactt tgatgtatgag	3960
	aggacaaggg ttgaatatga caccaagcat ggtggctct agtggtatgc cagcaactat	4020
30	gagcaaccct cggattcccc aggcaaattgc acagcagttt ccatttcctc caaactacgg	4080
	aataagtctcgtc caggctttac tggggctacg actccccaga gcccacttat	4140
	gtcaccggca atggcacata cacagagtcc catgatgca cagtcgtcagg ccaaccagc	4200
35	ctatcaggcc ccctccgaca taaatggatg ggccgcagggg aacatggcg gaaacagcat	4260
	gttttcccgag cagttccac cacactttgg gcagcaagca aacaccagca tgtacagtaa	4320
	caacatgaac atcaatgtgt ccatggcgac caacacaggt ggcattgagca gcatgaacca	4380
40	gatgacagga cagatcagca tgacctcagt gacccgttg cctacgtcag ggctgtcctc	4440
	catgggtccc gagcaggta atgatcctgc tctgaggggg ggcaacctgt tccaaaccca	4500
	gctgcctgga atggatatga ttaagcagga gggagacaca acacggaaat attgctgaca	4560
45	ctgctgaagc cagttgttc ttcaatgtc cgggctcact tgctcaaaac acttccagtc	4620
	tggagagctg tgtctatgg tttcaaccca actgacatgc cagccgggtc tgcttagagca	4680
	gacaggcctg gccctgggttc ccagggtggc gtccactcgg ctgtggcagg aggagctgcc	4740
50	tcttccttgc acagtctgaa gctcgcatcc agacagtgc tcagtctgtt cactgcattc	4800
	accttagtgc aacttagatc tctcctgcaa aagtaaatgt tgacaggcaa atttcataacc	4860
	catgtcagat tgaatgtatt taaatgtatg tatttaagga gaaccatgct ctgttctgt	4920
55	tcctgttcgg ttccagacac tggtttcttg ctggctaac agtcttagtgc	4980

5	aaaagattaa gatttatct gggggaaaga aaagaatttt taaaaaaatt aaactaaaga	5040
	tgttttaagc taaagcctga atttgggatg gaagcaggac agacaccgtg gacagcgctg	5100
	tatttacaga cacacccagt gcgtgaagac caacaaagtc acagtcgtat ctctagaaaag	5160
10	ctctaaagac catgttgaa agagtctcca gttactgaac agatgaaaag gaggctgtga	5220
	gagggctgtt aacattagca aatattttt ccttgtttt tcttgttaa aaccaaactg	5280
	gttcacctga atcatgaatt gagaagaaat aatttcatt tctaaattaa gtccctttt	5340
15	gtttgatcag acagctgaa tcagcatctc ttcttcctg tcagcctgac tcttccttc	5400
	ccctctctca ttccccatac tccctatttt cattcctttt taaaaaata atataagcta	5460
	cagaaaccag gtaagccctt tatttcctta aatgtttgc cagccactta ccaattgcta	5520
20	agtattgaat ttcagaaaaa aaaaatgcat ttactggcaa ggagaagagc aaagtttaagg	5580
	cttgatacca atcgagctaa ggatacctgc tttggaagca tgtttattct gttccccagc	5640
	aactctggcc tccaaaatgg gagaaaacgc cagtgtgtt aaattgtatag cagatatcac	5700
25	gacagattta acctctgcca tgcgtttttt atttgtttt ttagcagtgc tgactaagcc	5760
	gaagtttgt aaggtacata aaatccaatt tataatgtaaa caagcaataa tttaagttga	5820
	gaacttatgt gtttaattt tataattttt gtgaggata catattgtgg aattgactca	5880
30	aaaatgaggt acttcagtt taaatttagat atcttcatac caatgtctcc taaaggtgtt	5940
	ttgtaaagga tatcaatgcc ttgatttagac ctaatttgta gacttaagac tttttatttt	6000
	ctaaacccctg tgattctgct tataagtcat ttatctaattc tataatgtatgcagccgctg	6060
35	taggaaccaa ttcttgattt ttatatgtttt atattcttc ttaatgaacc ttagaaagac	6120
	tacatgttac taagcaggcc acttttatgg ttgttttt	6158
40	<210> 5 <211> 460 <212> PRT <213> Homo sapiens <400> 5	
	Met Ser Ser Pro Thr Thr Ser Ser Leu Asp Thr Pro Leu Pro Gly Asn	
	1 5 10 15	
45	Met Ser Ser Pro Thr Thr Ser Ser Leu Asp Thr Pro Leu Pro Gly Asn	
	Gly Pro Pro Gln Pro Gly Ala Pro Ser Ser Ser Pro Thr Val Lys Glu	
	20 25 30	
50	Glu Gly Pro Glu Pro Trp Pro Gly Gly Pro Asp Pro Asp Val Pro Gly	
	35 40 45	
	Thr Asp Glu Ala Ser Ser Ala Cys Ser Thr Asp Trp Val Ile Pro Asp	
	50 55 60	

5 Pro Glu Glu Glu Pro Glu Arg Lys Arg Lys Lys Gly Pro Ala Pro Lys
65 70 75 80

Met Leu Gly His Glu Leu Cys Arg Val Cys Gly Asp Lys Ala Ser Gly
85 90 95

10 Phe His Tyr Asn Val Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg
100 105 110

15 Arg Ser Val Val Arg Gly Gly Ala Arg Arg Tyr Ala Cys Arg Gly Gly
115 120 125

Gly Thr Cys Gln Met Asp Ala Phe Met Arg Arg Lys Cys Gln Gln Cys
130 135 140

20 Arg Leu Arg Lys Cys Lys Glu Ala Gly Met Arg Glu Gln Cys Val Leu
145 150 155 160

25 Ser Glu Glu Gln Ile Arg Lys Lys Ile Arg Lys Gln Gln Gln Glu
165 170 175

Ser Gln Ser Gln Ser Gln Ser Pro Val Gly Pro Gln Gly Ser Ser Ser
180 185 190

30 Ser Ala Ser Gly Pro Gly Ala Ser Pro Gly Gly Ser Glu Ala Gly Ser
195 200 205

35 Gln Gly Ser Gly Glu Gly Glu Gly Val Gln Leu Thr Ala Ala Gln Glu
210 215 220

Leu Met Ile Gln Gln Leu Val Ala Ala Gln Leu Gln Cys Asn Lys Arg
225 230 235 240

40 Ser Phe Ser Asp Gln Pro Lys Val Thr Pro Trp Pro Leu Gly Ala Asp
245 250 255

45 Pro Gln Ser Arg Asp Ala Arg Gln Gln Arg Phe Ala His Phe Thr Glu
260 265 270

Leu Ala Ile Ile Ser Val Gln Glu Ile Val Asp Phe Ala Lys Gln Val
275 280 285

50 Pro Gly Phe Leu Gln Leu Gly Arg Glu Asp Gln Ile Ala Leu Leu Lys
290 295 300

55 Ala Ser Thr Ile Glu Ile Met Leu Leu Glu Thr Ala Arg Arg Tyr Asn
305 310 315 320

5 His Glu Thr Glu Cys Ile Thr Phe Leu Lys Asp Phe Thr Tyr Ser Lys
325 330 335

10 Asp Asp Phe His Arg Ala Gly Leu Gln Val Glu Phe Ile Asn Pro Ile
340 345 350

15 Phe Glu Phe Ser Arg Ala Met Arg Arg Leu Gly Leu Asp Asp Ala Glu
355 360 365

20 Tyr Ala Leu Leu Ile Ala Ile Asn Ile Phe Ser Ala Asp Arg Pro Asn
370 375 380

25 Val Gln Glu Pro Gly Arg Val Glu Ala Leu Gln Gln Pro Tyr Val Glu
385 390 395 400

30 Ala Leu Leu Ser Tyr Thr Arg Ile Lys Arg Pro Gln Asp Gln Leu Arg
405 410 415

35 Phe Pro Arg Met Leu Met Lys Leu Val Ser Leu Arg Thr Leu Ser Ser
420 425 430

40 Val His Ser Glu Gln Val Phe Ala Leu Arg Leu Gln Asp Lys Lys Leu
435 440 445

45 Pro Pro Leu Leu Ser Glu Ile Trp Asp Val His Glu
450 455 460

50 <210> 6
<211> 1383
<212> DNA
<213> Homo sapiens
<400> 6
atgtcctctc ctaccacgag ttccctggat accccctgc ctggaaatgg ccccccctcag 60
cctggcgccc cttttcttc acccactgta aaggaggagg gtccggagcc gtggcccggg 120
ggtccggacc ctgatgtccc aggcactgat gaggccagct cagcctgcag cacagactgg 180
gtcatcccaag atcccaaga ggaaccagag cgcaagcgaa agaaggccc agcccccgaag 240
atgctgggcc acgagcttg ccgtgtctgt ggggacaagg cctccggctt ccactacaac 300
gtgctcagct gcgaaggctg caaggcgttc ttccggcgca gtgtggtccg tggggggcc 360
aggcgctatg cctgccccggg tggcggaacc tgccagatgg acgcttcat gcggcgcaag 420
tgccagcagt gccggctgctg caagtgcag gaggcaggga tgagggagca gtgcgtcctt 480
tctgaagaac agatccggaa gaagaagatt cggaaacagc agcaggagtc acagtcacag 540
tcgcagtcac ctgtggggcc gcagggcagc agcagctcag cctctgggcc tggggcttcc 600

55

EP 1 407 774 A1

5	cctgggtggat ctgaggcagg cagccaggc tccggggaaag gcgagggtgt ccagctaaca gcggctcaag aactaatgat ccagcagttt gtggcgcccc aactgcagtg caacaaacgc	660 720
10	tccttctccg accagccaa agtcacgccc tggccctgg gcgcagaccc ccagtcgg gatgcccgc agcaacgctt tgcccacttc acggagctgg ccatcatctc agtccaggag atcgtggact tcgctaagca agtgcctgg ttcctgcagc tggccggga ggaccagatc gccttcctga aggcatccac tatcgagatc atgctgctag agacagccag ggcgtacaac	780 840 900 960
15	cacgagacag agtgtatcac cttcttgaag gacttcaccc acagcaagga cgacttccac cgtgcaggcc tgcaggtgga gttcatcaac cccatctcg agttctcgcg ggccatgcgg	1020 1080
20	cggctggcc tggacgacgc tgagtacgccc ctgctcatcg ccatcaacat cttctcgcc gaccggccca acgtgcagga gccgggcccgt gtggaggcgt tgcaagcagcc ctacgtggag gcgctgtgt cctacacgcg catcaagagg ccgcaggacc agtcgcgtt cccgcgcgt ctcatgaagc tggtaggcct gcgcacgctg agtcgtgtgc actcggagca ggtcttcgccc	1140 1200 1260 1320
25	ttgcggctcc aggacaagaa gctgccgcct ctgctgtcgg agatctggga cgtccacqag tga	1380 1383
30	<210> 7 <211> 49 <212> DNA <213> Homo sapiens	..
35	<400> 7 ggggacaagt ttgtacaaaa aaggcaggctc gttcgcaaa tgccgtcag	49
40	Met Ser Leu Trp Leu Gly Ala Pro Val Pro Asp Ile Pro Pro Asp Ser 1 5 10 15	
45	Ala Val Glu Leu Trp Lys Pro Gly Ala Gln Asp Ala Ser Ser Gln Ala 20 25 30	
50	Gln Gly Gly Ser Ser Cys Ile Leu Arg Glu Glu Ala Arg Met Pro His 35 40 45	
55	Ser Ala Gly Gly Thr Ala Gly Val Gly Leu Glu Ala Ala Glu Pro Thr 50 55 60	
60	Ala Leu Leu Thr Arg Ala Glu Pro Pro Ser Glu Pro Thr Glu Ile Arg 65 70 75 80	

5 Pro Gln Lys Arg Lys Lys Gly Pro Ala Pro Lys Met Leu Gly Asn Glu
 85 90 95
 Leu Cys Ser Val Cys Gly Asp Lys Ala Ser Gly Phe His Tyr Asn Val
 100 105 110
 10 Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Val Ile Lys
 115 120 125
 15 Gly Ala His Tyr Ile Cys His Ser Gly Gly His Cys Pro Met Asp Thr
 130 135 140
 Tyr Met Arg Arg Lys Cys Gln Glu Cys Arg Leu Arg Lys Cys Arg Gln
 145 150 155 160
 20 Ala Gly Met Arg Glu Glu Cys Val Leu Ser Glu Glu Gln Ile Arg Leu
 165 170 175
 25 Lys Lys Leu Lys Arg Gln Glu Glu Gln Ala His Ala Thr Ser Leu
 180 185 190
 Pro Pro Arg Arg Ser Ser Pro Pro Gln Ile Leu Pro Gln Leu Ser Pro
 195 200 205
 30 Glu Gln Leu Gly Met Ile Glu Lys Leu Val Ala Ala Gln Gln Cys
 210 215 220
 35 Asn Arg Arg Ser Phe Ser Asp Arg Leu Arg Val Thr Pro Trp Pro Met
 225 230 235 240
 Ala Pro Asp Pro His Ser Arg Glu Ala Arg Gln Gln Arg Phe Ala His
 245 250 255
 40 Phe Thr Glu Leu Ala Ile Val Ser Val Gln Glu Ile Val Asp Phe Ala
 260 265 270
 45 Lys Gln Leu Pro Gly Phe Leu Gln Leu Ser Arg Glu Asp Gln Ile Ala
 275 280 285
 Leu Leu Lys Thr Ser Ala Ile Glu Val Met Leu Leu Glu Thr Ser Arg
 290 295 300
 50 Arg Tyr Asn Pro Gly Ser Glu Ser Ile Thr Phe Leu Lys Asp Phe Ser
 305 310 315 320
 55 Tyr Asn Arg Glu Asp Phe Ala Lys Ala Gly Leu Gln Val Glu Phe Ile
 325 330 335

5 Asn Pro Ile Phe Glu Phe Ser Arg Ala Met Asn Glu Leu Gln Leu Asn
340 345 350

Asp Ala Glu Phe Ala Leu Leu Ile Ala Ile Ser Ile Phe Ser Ala Asp
355 360 365

10 Arg Pro Asn Val Gln Asp Gln Leu Gln Val Glu Arg Leu Gln His Thr
370 375 380

15 Tyr Val Glu Ala Leu His Ala Tyr Val Ser Ile His His Pro His Asp
385 390 395 400

Arg Leu Met Phe Pro Arg Met Leu Met Lys Leu Val Ser Leu Arg Thr
405 410 415

20 Leu Ser Ser Val His Ser Glu Gln Val Phe Ala Leu Arg Leu Gln Asp
420 425 430

25 Lys Lys Leu Pro Pro Leu Leu Ser Glu Ile Trp Asp Val His Glu
435 440 445

30

35

40

45

50


55

Claims

1. A compound of the formula (1), or pharmaceutical acceptable salts or solvates thereof according to formula (1)

5

10



15

wherein: R₁, R₂, R₃ and/or R₄, is independently from each other H, halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, R₅ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, R₆ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, and R₇ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl.

20

25

2. A compound according to claim 1 wherein R₆ and R₇ are taken together with nitrogen to form a heterocycle or substituted heterocycle or a heteroaryl or substituted heteroaryl according to the following formula (2).

30

35



3. A compound according to claim 2, or pharmaceutical acceptable salts or solvates thereof, wherein:

40

45


R₁, R₂, R₃, R₄, is H, halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, and R₅ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl.

50

4. A compound according to claim 1 wherein R₆ and R₇ are taken together with nitrogen to form the heterocycle according to the following formula (3)

55

5




10

5. A compound according to any of claims 1 to 3 of the following formula (4)

15

formula (4)

20




25

6. A compound according to any of claims 1 to 3 of the following formula (5)

30

formula (5)

35




40

7. A compound according to any of claims 1 to 3 of the following formula (6)

45

formula (6)

50




55

8. A compound according to any of claims 1 and 4 wherein R₆ and R₇ are taken together with nitrogen to form the heterocycle according to the following formula (7)

formula (7)

5




10

9. A compound according to claim 1 according to the following formula (8)

15

formula (8)

20




25

30 10. A compound according to claims 1 and 4 according to the following formula (8)

35

formula (8)

40



45

11. A compound according to any of claims 1 to 10 wherein said compound is capable of binding the NR1H3 receptor protein or a portion thereof according to SEQ ID NO. 1 or a mammalian homologue thereof.

50 12. A compound according to any of claims 1 to 10 wherein said compound is capable of binding the NR1H2 receptor protein or a portion thereof or a mammalian homologue thereof.

13. Use of a compound according to any of claims 1 to 12 as a medicament

55 14. A method for prevention or treatment of a NR1H3 and/or NR1H2 receptor protein mediated disease or NR1H3 and/or NR1H2 receptor protein homologue mediated disease or condition in a mammal comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 12, wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to claims 1 to 13 to

the NR1H3 and/or NR1H2 receptor proteins or to the NR1H3 and/or NR1H2 receptor protein homologues.

- 5 15. A method for prevention or treatment of a NR1H3 receptor protein and/or NR1H2 receptor protein mediated disease or condition according to claim 14, wherein said mammal is a human.
- 10 16. A method for regulating the cholesterol synthesis and/or transport in a mammal which comprises activating the NR1H3 and/or NR1H2 receptors with a therapeutically effective amount of a compound according to claims 1 to 12.
- 15 17. A method of treating in a mammal a disease which is affected by cholesterol, triglyceride, or bile acid levels comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 12.
18. A method of treating atherosclerosis, alzheimers disease, lipid disorders, obesity or a cardiovascular disorder in a mammal, in particular a human, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 12.
19. A method according to any of claims 14 to 18 wherein the expression of ABCA 1 and/or ABCG1 and/or ABCG5 and/or ABCG8 is increased.
- 20 20. A method according to any of claims claim 14 to 19 wherein the expression of the cholesterol 7 α hydroxylase and/or the activity of the cholesteryl ester transfer protein is increased.
- 25 21. A method of blocking in a mammal the cholesterol or fatty acid absorption in the intestine of a mammal in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 12.
22. A method for treating obesity in a mammal comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 12.
- 30 23. A method of modulating a gene whose expression is regulated by the NR1H3 and/or NR1H2 receptor in a mammal comprising administering a therapeutically effective amount of a compound according to claims 1 to 10.
- 35 24. A method according to any of claims claim 14 to 19 wherein the expression of the cholesterol 7 α hydroxylase and/or the activity of the cholesteryl ester transfer protein is enhanced.
- 25 25. Use of a compound according to any of claims 1 to 12 wherein the mammal is a human
- 40 26. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for the prevention or treatment of a NR1H3 and/or NR1H2 receptor protein or NR1H3 and/or NR1H2 receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according claims 1 to 8 to the NR1H3 and/or NR1H2 receptor protein or NR1H3 and/or NR1H2 receptor protein homologue.
- 45 27. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for prevention or treatment of a NR1H3 and/or NR1H2 receptor protein mediated disease or condition according to claim 26, wherein the mammal is a human.
- 50 28. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for regulating the cholesterol transport system in a mammal by activating the NR1H3 and/or NR1H2 receptor.
29. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for regulating levels of cholesterol, triglyceride, and/or bile acid.
- 55 30. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for treating in a mammal atherosclerosis, alzheimer disease, gallstone disease, lipid disorders, obesity or a cardiovascular disorder.
31. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament capable for blocking in a mammal the cholesterol and/or fatty acid absorption in the intestine.

32. Use of the compound according to any of claims 1 to 12 for the manufacture of a medicament for treating obesity in a mammal.

5 33. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for modulating a gene whose expression is regulated by the NR1H3 and/or NR1H2 receptor.

10 34. Use of a compound according to any of claims 1 to 12 in a mammal for the selective up-regulation of one or more genes selected from the group consisting of ABCA1, ABCG1, ABCG5 and ABCG8 and a down-regulation of one or more of the genes selected from the group comprising FAS and SREBP-1c, said compound showing a larger difference in regulation of the two groups of genes when compared with the regulatory behavior of T0901317 on both groups of genes.

35. Use of a compound according to claims 28, 30, 31, 32, and 34 wherein the mammal is a human.

15

20

25

30

35

40

45

50

55

Fig.1:




Fig. 2 : Measurement parameters employed by the Wallace VICTOR2V™ Multilabel Counter:

Number of repeats	1
plate: GREINER FIA-Plate black 384 well med. binding	
Measurement height	3.50 mm
Label technology	TR-F Lance
Emission filter name	D615
Emission filter slot	A1
Emission aperture	Normal
Excitation filter	D340
Delay	50 µs
Window time	400 µs
Cycle	1000 µs
Light integrator capacitors	1
Light integrator ref. level	95
Flash energy area	High
Flash energy level	223
Flash absorbance measurement	No
Beam	Normal
Label technology	TR-F Lance
Emission filter name	D665
Emission filter slot	A8
Emission aperture	Normal
Excitation filter	D340
Delay	50 µs
Window time	400 µs
Cycle	1000 µs
Light integrator capacitors	1
Light integrator ref. level	95
Flash energy area	High
Flash energy level	223
Flash absorbance measurement	No
Beam	Normal

Fig. 3 A and B:**A**

```

1 mslwlgapvp dippdsavel wkgqaqdass qaaggsscil reearmphaa ggttagvglea
61 aeftalltra eppsepteir pgkrkkgpap kmlgnelcsv cgdkasgfhv nvlsciegckg
121 ffrrvikga hyichsgghc pmdtymrrkc qecrlrkcrq agmreecvls eeqirlkklk
181 rqeheeqahat slpprressp qilpqlsseq lgimeklvaq qqqcnrrsfs drlrvtpwpm
241 apdphsrear qqrfahtel aivsvqeivd fakqlpgflq lsredqiall ktsaievml
301 etsrrynpgs esitflkdfs ynredfakag lqvefinpif efsramnleq lndaefalll
361 aisisfsadrp nvqdqlqver lgntyvealh ayvsihhphd rlmfprrmlmk lvslrtlssv
421 hseqvfalrl qdkklpppls eiwdvhe

```

B

```

1 atgtccttgt ggctgggggc ccctgtgcct gacattcctc ctgactctgc ggtggagctg
61 tggaaagccag ggcacacagga tgcaagcagc caggcccagg gaggcagcag ctgcattcctc
121 agagaggaaag ccaggatgcc ccactctgc ggggtactg caggggtggg gctggaggct
181 gcagaaaaaggc cagccctgc cagcaggca gagccccctt cagaacccac agagatccgt
241 ccacaaaaagc ggaaaaaaggc gccagcccc aaaaatgctgg ggaacgagct atgcagcgtg
301 tgtggggaca aggccctcggg cttccactac aatgttctga gctgcgaggg ctgcaaggga
361 ttcttcggcc gcagcgtcat caaggagc cactacatct gccacagtgg cggccactgc
421 cccatggaca cctacatgcg tcgcaagtgc caggagtgtc ggcttcgcaa atgcccgtcag
481 gctggatgc gggaggatgc tgcctgtca gaagaacaga tcgcctgaa gaaactgaag
541 cggcaagagg aggaacagcgc tcatgcaca tccttgcccc ccaggcgttc ctcacccccc
601 caaatcctgc cccagctcag cccggaaacaa ctggcatga tcgagaagct cgtcgtcgc
661 cagacaacagt gtaaccggcg ctccctttct gaccggcttc gagtacgc ttggccatcg
721 gcaccaggatc cccatagccg ggaggcccg cagcagcgtt ttgcccactt cactgagctg
781 gccatcgatc ctgtgcaga gatagtgc tttgtcaac agctaccggg cttcctgcag
841 ctcagccggg aggacaggat tgcctgtca aagacctctg cgtacgaggt gatgttctg
901 gagacatctc ggaggtacaa cccggggat gagagtatca cttccctcaa ggatttcagt
961 tataaccggg aagacttgc caaagcaggg ctgcaagtgg aattcatcaa cccatcttc
1021 gagttctcca gggccatgaa tgagctgaa ctcaatgtc ccgaggttgc cttgtcatt
1081 gctatcagca tcttctctgc agaccggccc aacgtgcagg accagctcca ggtggagagg
1141 ctgcagcaca catatgtga agccctgcat gcctacgtct ccatccacca tccccatgac
1201 cgactgatgt tcccacggat gctaataaaa ctgggtgagcc tcgggaccct gagcagcgtc
1261 cactcagagc aagtgttgc actgcgtctg caggacaaaa agtcccacc gctgtctct
1321 gagatctggg atgtgcacga atga

```

1431

Fig. 3 C and D:

C

MLVKPLPDSE	EEGHDNQEAH	QKYETMQCFA	VSQPKSIKEE	GEDLQSCLIC	VARRVPMKER	60
PVIPSSESFT	TRQDLOGKIT	SLDTSTMRAA	MKPGWEDLVR	RCI0KFHA0H	EGESVSYAKR	120
HHHEVLRQGL	AFSQIYRFLS	SDGTLVAAQT	KSKLIRSOOTT	NEPQLVISLH	MLHREQNVCV	180
MNPDLTGQTM	GPKLNPISSN	SPAHQALCSG	NPGQDMTLSS	NINFPINGPK	EQMGMPPMGRF	240
GGSGGMNHVS	GMQATTPOGS	NYALKMNSPS	QSSPGMNPQO	PTSMILSPRRH	MSPGVAGSPR	300
IPPSQFSPAG	SLHSPVGVCs	STGNSHSYTN	SSLNALQALS	EGHGVSGLGSS	LASPDLKGMN	360
LQNSPVNMNP	PPLSKMGSLL	SKDCFGLYGE	PSEGTTQQAЕ	SSCHFGEQKE	TNDPNLPPAV	420
SSEADGOSR	LHDSKGOTKL	LQLLTTKSQD	MEPSPLASSL	SDTNKDSTGSS	LPGSGSTHGT	480
SLKEKHKLH	RLLQDSSSPV	DLAKLTAEAT	GKDLSEQESS	TAPGSEVTIK	QEPVSPKKKE	540
NALLRYLLDK	DDTKD1GLPE	ITPKLERLDS	KTDPASNTKL	IAMKTEKEEM	SEFPGDQPGS	600
ELDNLEEILD	DLQNSQLPQL	FPDTRPGAPA	GSVDKQAIIN	DLMQLTAEINS	PVTPVGAQKT	660
ALRISQSTFN	NPRPGQLGRL	LPNQNLPLDI	TLQSPTGAGP	FPPTRNNSPY	SVIPQPGMMG	720
NQGMIGNQGN	LGNSSTGMIG	NSASRPTMPS	GEWAPQSSAV	RVTCAATTSA	MNRPVQGGMI	780
RNFAASIPMR	PSSQPGQRQ	LQSQVMNIGP	SELEMMNGGP	QYSQQQAPEN	QTAPWPESIL	840
PIDQASFASQ	NRQPFQSSPD	DLLCPHAAE	SPSDEGALLD	QLYLALRNFD	GLEEIDRALG	900
IPELVSQSQA	VDPEQFSSQD	SNIMLEQKAP	VFPQQYASQA	QMAQGSYSPM	QDPNFHTMGQ	960
RP5YATLREQ	PRPGLRFATL	VQNQPNQLRL	QLQHRLQQAQQ	NRQFLMNQIS	NVSNVNLTLLR	1020
PGVPTQAFIN	AQMLAQRQRE	IINQHLLRQRQ	MHQQQQVQQR	TLMMRGQGLN	MTPSMVAPSG	1080
MPATMSNRFI	PQANAQOFPF	PPNYGISQOP	DPGFTGATTP	QSPLMSPRMA	HTOSPMQQS	1140
QANPAYQAPS	DINGWAQGNM	GGNSMFSQOS	PPHEFGQOANT	SMYSNNMNIN	VSMATNTGGM	1200
SSMNQMTGQI	SMTSVTSVPT	SGLSSMGPEQ	VNDPALRGGN	LFPNQLPGMD	MIKQEGDTTR	1260
KYC						1263

D

```

1 ggccggccga gcctcggtca cagttcggc ggcgaaggc acgcggccacg gcagccggca
61 cctgacggcg tgacccgaccc gagccgattt ctcttggatt tggctacaca cttatagatc
121 ttctgactg ttacaggca cagttctga tatgttgc agatgagtgg gatgggagaa
181 aatacctctg acccttcagg ggcagagaca agaaaggc acggaaatgtcc tgaccaactt
241 ggacccaggc cccaaaggaa cactgtaaaaa cgtaatctgt aacaggaaaaaaa taaaatata
301 gaagaacttgc cagagttgtat ttttgcataat ttaatgata tagacaactt taacttcaaa
361 cctgcacaaat tgtaatctt aaaaaggaaact gtgaaagccaa ttccgtcagat caaaggaaacaa
421 gagaaggcag cagtgccaa catagatgaa gtgcagaaggt cagatgttac ctctacagg
481 cagggtgtca tcgacaaaggaa tggcgtgggg cctatgtgc ttgaggccct tgatgggttc
541 ttctttgttag tgaaccttgc aggcaacgtt gtgttgc tgatgatgtt gacacagttat
601 ctaaggatc accagaagaatc gctgtatgaaacaaaatgtt atagcatctt gcatgttggg
661 gaccacacgg aattttgtcaaa aaacctgtc cccaaatgtca tagttaaaatg ggggatcttgc
721 gtctggcga cctccgagggc ggaacagccaa tacccctcaat tgcggatgc ttgtaaaacc
781 ttacccctgtca cagaaggaggaaatggcgtcatgaa taacccaggaa gtcctatcaga aatatggaaac
841 tatcgatgtc ttccgtgtct ctcaacccaaatggcgtcatgaa taacccaggaa gtcctatcaga aatatggaaac
901 gtccgttgc atttgcgtgg caaagaaggtt tcccatgaaatggcgtcatgaa taacccaggaa ttcttccctc
961 atcagaaatgtt attcactactc gccaggatctt cccaaatgtca tagttaaaatg ggggatcttgc
1021 caccatgaga gcaacccatgaa aaccaggctg ggaggacccatgaaatggcgtcatgaa taatggaaac
1081 gtccatcgcc cagcatgaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1141 actgagacaa ggttggcat tcagtcaat ctatgtttt tccctgttgc atggactctt
1201 tggatgtc tccgtgtctt ctcaacccaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1261 tggatgtc tccgtgtctt ctcaacccaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1321 gactggacaa acgtggggc agccactgaa tccaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1381 ggcctgtgc agtggggcacc caggtcggaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1441 cataaaatggc cccaaaggaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1501 aatggacccatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1561 aatggacccatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1621 ttcaccaagg ctcgtgtctt ctcaacccaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1681 gttttccctc gcaaggaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1741 ccatagttat accacacggc cccatgtcacttccggc ctcagccggg ggcacgggg
1801 ctatccatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1861 agttaatatg aatccctccccc cactcggaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1921 tggactatatg ggggaggccctt ctcaaggatgtt aacttggacaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
1981 tggagagacaa aaggaaacaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2041 tgacccggcag accagactgtc atgacacggaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2101 caccatgtcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2161 agactccaca ggttggcatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2221 gcatataatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2281 aacaggcggaaatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2341 agaaggactgtc attaaacaag agccgggtggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2401 ctatccatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2461 tgagagactgtc gacgttgcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2521 tgagaaggatgttgcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2581 ggaggagatttgcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac
2641 gcaaggccgc cccatgtcacttccggc ctcagccggg ggcacgggg
2701 cacacccatggcgtcatgaa taacccaggaaatggcgtcatgaa taatggaaac

```

Fig. 3 D (continued):

2761 acagagcaact tttataataacc caagaccagg gcaactgggc aggttattgc caaaccagaa
 2821 ttaccacatt gacatcacat tgcggcc aactgggtct ggaccttcc cacaatcag
 2881 aaacagtat ccctactcg tagtacccat gcggccatgc aggtggatcc tgctttctcg
 2941 aggaacccaa gggaaatttag gggaaacatcg cacagaaatg attgtaaca tgctttctcg
 3001 gcctactatg ccacatggag aatgggcac gcaagatcg gctgtgagag taccatgtgc
 3061 tgcttacccatggccatcg aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3121 cagcatccccccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3181 catgatataatggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3241 acaagttctcccaaatcaga ctggccatgc gctgaaatgc atccgtctca tagaccaggc
 3301 gtctttccggcc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3361 acatccgtcaatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3421 cttgcggaaat tttatggcc tggaggagat tgatagagcc ttaggaataccatgtct
 3481 cagccagccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3541 ggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3601 tagtattttccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3661 cacactccgtatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3721 aaataactaaatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3781 tttatggatccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3841 acaggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3901 tttatggatccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 3961 aggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4021 gacccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4081 aataatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4141 gtcacccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4201 ctatccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4261 gttttccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4321 caacatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4381 gatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4441 catggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4501 gtcgccttgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4561 ctgcgcgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4621 tggatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4681 gacccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4741 tcttccttcgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4801 acatgtgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4861 catgtgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4921 tcctgttcgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 4981 aaaatggatccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5041 tttatggatccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5101 tttatggatccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5161 ctccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5221 gggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5281 gttccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5341 gtttgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5401 cccttccttcgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5461 cagaaatggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5521 agtattttatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5581 ctgcgcgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5641 aacttcgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5701 gagatgttcgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5761 gaatggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5821 gaatggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5881 aatggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 5941 ttgttgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 6001 cttttatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 6061 tagggccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc
 6121 tttatggatccatgc aatggccatgc ccaaggaggt atgatccgga acccaggcgc

Fig. 3 E:

```

1 MSSPTTSSLD TPLPGNGPPQ PGAPSSSPTV KEEGPEPWPG GPDPDVPGTD EASSACSTDW
61 VIPDPEEPE RKRKKGPAPK MLGHELCRVC GDKASGFHYN VLSCEGCKGF FRRSVVRGGA
121 RRYACRGGGT CQMDAFMRRK CQQCRLRKCK EAGMREQCVL SEEQIRKKKI RKQQQESQSQ
181 SQSPVGPQGS SSSASGPGAS PGGSEAGSQG SGEGEVGQLT AAQELMIQQL VAAQLQCNKR
241 SFSDQPKVTP WPLGADPQSR DARQQRFAHF TELAIIISVQE IVDFAKQVPG FLQLGREDQI
301 ALLKASTIEI MILLETARRYN HETECITFLK DFTYSKDDFH RAGLQVEFIN PIFEFSRAMR
361 RLGLDDAEYA LLIAINIFSA DRPNVQEPEGR VEALQQPYVE ALLSYTRIKR PQDQLRFPROM
421 LMKLVSLRTL SSVHSEQVFA LRLQDKKLPP LLSEIWDVHE

```






Fig. 3 F:

```

1 atgtcctctc ctaccacgag ttccctggat acccccctgc ctggaaatgg ccccccctcag
61 cctggcgccc cttcttcttc acccactgt aaggaggagg gtccggagcc gtggcccccgg
121 ggtccggacc ctgatgtccc aggcactgat gaggccagct cagcctgcag cacagactgg
181 gtcatcccag atcccgaaaga ggaaccagag cgcaagcgaa agaaggggccc agccccgaag
241 atgctgggcc acgagctttg ccgtgtctgt ggggacaagg cctccggctt ccactacaac
301 gtgctcagct gcgaaggctg caagggcttc ttccggcgca gtgtggctcg tggggggcc
361 aggcgcctatg cctgccccggg tggcggaaacc tgccagatgg acgcattcat gcggcgcaag
421 tgccagcagt gccggctgcg caagtgcagag gaggcaggga tgagggagca gtgcgtcctt
481 tctgaagaac agatccggaa gaagaagatt cgaaacacgc agcaggagtc acagtcacag
541 tcgcagtcac ctgtggggcc gcagggcagc agcagctcag cctctggcc tggggcttcc
601 cctgggtggat ctgaggcagg cagccaggcc tccggggaaag gcgagggtgt ccagctaaca
661 gcggtcaag aactaatgtatgc ctagcagttt gtcggccccc aactgcagtg caacaaacgc
721 tccttctccg accagcccaa agtcacgccc tggcccttgg ggcgcagaccc ccagtcccgaa
781 gatgcccgcg agcaacgcctt tgcccacttc acggagctgg ccatcatctc agtccaggag
841 atcgtggact tcgctaagca agtgccttgtt ttcctgcagc tggggccggga ggaccagatc
901 gcccctctga aggcatccac tatcgagatc atgctgttag agacaggccag ggcgcataaac
961 cacaacacag agtgtatcac cttcttgcag gacttcaccc acagcaagga cgcacttccac
1021 cgtgcaggcc tgcagggtggaa gttcatcaac cccatcttcg agttctcgcc ggccatgcgg
1081 cggctggcc tggacgcgc tgagtaagcc ctgctcatcg ccatcaacat cttctcgcc
1141 gaccggccca acgtgcagga gcccggccgc gtggaggcgt tgccagcagcc ctacgtggag
1201 ggcgtgtgtt cctacacgcg catcaagagg cccaggacc agtgcgcctt cccgcgcatg
1261 ctcatgaagc tggtgagccct ggcgcacgcgt agtctgtgc actcgagca ggtcttcgccc
1321 ttgcggctcc aggacaagaa gctgcggccct ctgctgtcgg agatctggga cgtccacgcg
1381 tga

```

Fig. 4 A:

MOLNAME	MOLECULE STRUCTURE	EC50 AVG	EFFIC AVG
LN0000003252		0.59	110
LN0000007459		0.12	129
LN0000011283		0.18	137
TR1040007465		1.2	114
LN0000007460		2,6	111
LN0000006500		0,34	133



			
LN0000006494		0,23	112

Fig. 4 A (cont.)





MOLNAME	MOLECULE STRUCTURE	EC50 AVG	EFFIC AVG
LN0000007364		1.5	101
LN0000003492		0.11	115
LN0000007180		0.15	128
LN0000007179		0.78	127

Fig. 4 A (cont.):

Fig. 5:




Fig. 6

Liver X receptor alpha, LXR α (NM_005693)
Cholesterol 7 α hydroxylase, Cyp7A1 (NM_000780)
FAS (NM_004104)
Stearyl CoA desaturase, SCD (XM_030447)
Sterol Response Element Binding Protein 1C, SREBP-1C (NM_004176)
ATP binding cassette transporter A1; ABCA1 (NM_005502)
ATP binding cassette transporter G1; ABCG1 (XM_032950)
ATP binding cassette transporter A1; ABCG5 (NM_031884)
ATP binding cassette transporter A1; ABCG8 AF324494
Apolipoprotein E, apoE (NM_000041)
Apolipoprotein C-I, apoc-I (NM_001645)
Apolipoprotein C-II apoc-II (NM_000483)
Apolipoprotein C-IV, apoC-IV (U32576)
Lipoprotein Lipase, LPL (M15856)
Cholesteryl Ester Transfer Protein, CETP (NM_000078)

Fig. 7:




Fig. 8A:




Fig. 8B




Fig. 9





Fig. 10:





European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 02 02 0255
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 02 062798 A (REDDY RESEARCH FOUNDATION) 15 August 2002 (2002-08-15) * claim 1 * * page 106, line 22 - page 107, line 6 * * page 1, line 17 - page 2, line 16 * ---	1,13-33	A61K31/517 C07D239/95 C07D401/12 C07D403/04 A61P3/06
X	WO 97 20823 A (CRISCIONE LEOLUCA ;YAMAGUCHI YASUCHIKA (CH); CIBA GEIGY AG (CH); M) 12 June 1997 (1997-06-12) * page 74; example 38 * * page 1, paragraph 1 * ---	1,13,18, 22,30, 32,35	
X	WO 02 48152 A (BAKTHAVATCHALAM RAJAGOPAL ;BRIELMANN HARRY L (US); ELLIOTT RICHARD) 20 June 2002 (2002-06-20) * page 59; example 12 * * page 6, paragraph 17 * ---	1,13,18, 22,30, 32,35	
		-/-	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07D A61K A61P
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search	Date of completion of the search	Examiner	
MUNICH	18 December 2002	Kollmannsberger, M	
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>	
EPO FORM 1503/03-82 (P04/C07)			



Claims 14-25, 34, 35 are directed to a method of treatment of the human/animal body (Article 52(4) EPC). Insofar as the claims could be searched, the search has been carried out based on the alleged effects of the compounds.

Claim(s) searched completely:
4-10

Claim(s) searched incompletely:
1-3, 11-35

Reason for the limitation of the search:

Claims 1-12 encompass a large number of known compounds. The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 84 EPC). Additionally, support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC is to be found, for only a very small proportion of the compounds and methods claimed. For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search is only complete for:

Compounds according to claims 4-10 which are mentioned in the prior art to have useful properties in the treatment of the diseases mentioned in claims 29-32; compounds as such according to claims 4-10.

Only some documents relevant to other subject-matter of the claims have been cited for illustration.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 02 02 0255

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
D,A	<p>COLLINS, J. L. ET AL.: "Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines" JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, 2002, pages 1963-1966, XP002225147 * the whole document *</p> <p>---</p>	1-33	
X	<p>GUPTA C M ET AL: "Drugs acting on the central nervous system. Syntheses of substituted quinazolones and quinazolines and triazepino- and triazocinoquinazolones" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 11, no. 2, 26 February 1968 (1968-02-26), pages 392-395, XP002156695 ISSN: 0022-2623 * examples 13-16,22,23,38; table 2 *</p> <p>---</p>	1,4,8,13	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	<p>MANABU HORI ET AL: "Novel 4-Substituted 2-Piperazinylquinazolines as potent Anticonvulsive and Antihypoxic Agents" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 38, no. 5, 1990, pages 1286-1291, XP002128282 ISSN: 0009-2363 * examples 3A-3H; table II *</p> <p>---</p>	1	
X	<p>US 3 609 152 A (HESS HANS-JURGEN E ET AL) 28 September 1971 (1971-09-28) * examples III-X *</p> <p>---</p> <p>---</p> <p>-/-</p>	1,4,8,13	



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 02 02 0255

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	<p>DATABASE CHEMCATS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002225148 Order Number: TRG10400#07364-D; TRG10400#01891-D; TRG10400#01815-D; TRG10400#01814-D; TRG10400#01812-D; TRG10400#01811-D; TRG10400#01809-D; TRG10400#01736-D; TRG10400#01735-D; TRG10400#01732-D; TRG10400#01729-D & "Chem. Folio" 15 January 2001 (2001-01-15) , LION BIOSCIENCE AG , HEIDELBERG, GERMANY -----</p>	1-3,9	

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 02 0255

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-12-2002

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 02062798	A	15-08-2002	WO	02062798 A2	15-08-2002
			WO	02062799 A1	15-08-2002
			US	2002169175 A1	14-11-2002
<hr/>					
WO 9720823	A	12-06-1997	AU	7692996 A	27-06-1997
			WO	9720823 A2	12-06-1997
			ZA	9610020 A	01-06-1997
<hr/>					
WO 0248152	A	20-06-2002	AU	2027602 A	24-06-2002
			WO	0248152 A2	20-06-2002
<hr/>					
US 3609152	A	28-09-1971	BE	678216 A	22-09-1966
			DE	1620127 A1	12-03-1970
			FR	5267 M	31-07-1967
			GB	1062357 A	22-03-1967
			GB	1174272 A	17-12-1969
			GB	1174273 A	17-12-1969
<hr/>					